{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":84,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":84,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12","author_layer_release":"2026-06-26"},"query_hash":"9ccf8b315765","filters":{"venue":"Therapeutic Advances in Medical Oncology"}},"results":[{"id":"W2111842868","doi":"10.1177/1758834011422556","title":"An overview of the c-MET signaling pathway","year":2011,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":864,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Signal transduction; Hepatocyte growth factor; Receptor tyrosine kinase; Cancer research; Medicine; Tyrosine kinase; Cell biology; C-Met; Motility; Receptor; Biology; Internal medicine","authors":[{"name":"Shawna Organ","is_ca":true},{"name":"Ming‐Sound Tsao","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1090998566900658,"gpt":0.4107995393709702,"spread":0.3016996826809044,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009384079,0.0001121448,0.000488163,0.00005146335,0.00002786423,3.895179e-7,0.0003227105,0.0002975953,0.001117984],"category_scores_gemma":[0.0001280202,0.0000664187,0.0000696977,0.0002134036,0.0007884065,0.00007261836,0.00005801101,0.0004700228,0.00001374853],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004875474,"about_ca_system_score_gemma":0.0004800672,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001390817,"about_ca_topic_score_gemma":0.00003515853,"domain_scores_codex":[0.9982824,0.0006591848,0.0003668483,0.0002066266,0.0002470291,0.0002379101],"domain_scores_gemma":[0.9990841,0.0002627862,0.0001349711,0.0003275939,0.00006003127,0.0001305501],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"theoretical_or_conceptual","study_design_scores_codex":[0.001905687,0.002365894,0.07371753,0.0001997166,0.0001064825,0.0004345773,0.007294893,0.00001677734,0.01550456,0.05472069,0.00001964382,0.8437135],"study_design_scores_gemma":[0.01711885,0.02582063,0.2094195,0.001101804,0.0005373871,0.001847814,0.004330296,0.0006200117,0.04272555,0.4696045,0.2260323,0.0008413339],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9491566,0.03172854,0.0004640837,0.000711983,0.001068982,0.0004197224,0.000004374221,0.00004234412,0.01640339],"genre_scores_gemma":[0.9917508,0.001529776,0.001137737,0.005408177,0.0001135152,0.00001899565,0.000003512094,0.0000103254,0.00002717133],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8428722,"threshold_uncertainty_score":0.9997951,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2122895515","doi":"10.1177/1758834011422557","title":"c-MET as a potential therapeutic target and biomarker in cancer","year":2011,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Liver physiology and pathology","field":"Medicine","cited_by":362,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; Ontario Institute for Cancer Research","funders":"","keywords":"Medicine; Hepatocyte growth factor; C-Met; Cancer research; Receptor tyrosine kinase; Cabozantinib; Angiogenesis; Tyrosine kinase; Cancer; Targeted therapy; Oncology; Internal medicine; Receptor; VEGF receptors","authors":[{"name":"J. Rafael Sierra","is_ca":true},{"name":"Ming‐Sound Tsao","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04271645134954376,"gpt":0.3864415472270487,"spread":0.3437250958775049,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006438827,0.0002055199,0.0006518933,0.0002004045,0.00003821179,0.000001568662,0.0001792415,0.0005209573,0.003571507],"category_scores_gemma":[0.00006634969,0.000156649,0.00005396931,0.0002542814,0.0009996839,0.0001098363,0.00007899526,0.0006707883,0.0000336062],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009821907,"about_ca_system_score_gemma":0.0003837129,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001442864,"about_ca_topic_score_gemma":0.0001847187,"domain_scores_codex":[0.9979886,0.0004716373,0.0004178542,0.0004209419,0.0002153058,0.0004856673],"domain_scores_gemma":[0.9992244,0.0002675411,0.00009619953,0.0001999461,0.000021947,0.0001899168],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.00428738,0.001253694,0.1120447,0.00008637978,0.0001418846,0.002547498,0.002794667,0.00000330646,0.003865323,0.006241722,0.00001949654,0.8667139],"study_design_scores_gemma":[0.01378766,0.005636417,0.7510293,0.000233081,0.0002184983,0.001934713,0.001107516,0.0009581629,0.000629598,0.1346308,0.08928251,0.0005517461],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8966302,0.07772268,0.0008825997,0.005008004,0.001430139,0.0007414886,0.000005648673,0.00007469294,0.01750457],"genre_scores_gemma":[0.9760672,0.01140845,0.0009110435,0.01128197,0.0001020471,0.0001095042,0.000007101373,0.00001996913,0.00009268531],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8661622,"threshold_uncertainty_score":0.9973394,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2139562398","doi":"10.1177/1758834010395342","title":"Health-related quality of life and cancer clinical trials","year":2011,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer survivorship and care","field":"Medicine","cited_by":226,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Clinical trial; Cancer; Quality of life (healthcare); Quality (philosophy); Intensive care medicine; Oncology; Internal medicine; Nursing","authors":[{"name":"David Osoba","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.299585135842967,"gpt":0.554391340122369,"spread":0.254806204279402,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.01207258,0.0001348149,0.002035906,0.00007900237,0.00002292177,9.792931e-7,0.0001315903,0.0003880049,0.001961036],"category_scores_gemma":[0.002550748,0.00009802461,0.0001442121,0.0002088736,0.0008103953,0.00005280556,0.00004739355,0.0006178388,0.000003835694],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001014391,"about_ca_system_score_gemma":0.001378466,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002119633,"about_ca_topic_score_gemma":0.005926199,"domain_scores_codex":[0.9939582,0.002754254,0.002307749,0.0003036473,0.0003907115,0.0002853748],"domain_scores_gemma":[0.9959347,0.002619098,0.0006827488,0.0002227741,0.00007096863,0.0004697619],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.002567114,0.000386682,0.1342501,0.0001658775,0.00009942108,0.00001612295,0.001636033,1.801107e-7,0.000008263589,0.002432551,0.00003890473,0.8583987],"study_design_scores_gemma":[0.02922977,0.007518109,0.638817,0.0008397858,0.0002549613,0.00008858007,0.004122472,0.0002145473,0.00007970069,0.02440488,0.2938994,0.0005307471],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6689373,0.2957457,0.001233437,0.0196573,0.003500723,0.0009642637,0.00001748076,0.00007021348,0.009873592],"genre_scores_gemma":[0.9287177,0.06162009,0.0002326713,0.00911276,0.0001892297,0.00004906674,0.00000378585,0.00001329951,0.00006136441],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.857868,"threshold_uncertainty_score":0.9989513,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2086837512","doi":"10.1177/1758834012475152","title":"Immunotherapeutic approaches in triple-negative breast cancer: latest research and clinical prospects","year":2013,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":166,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Triple-negative breast cancer; Medicine; Breast cancer; Immunotherapy; Immune system; Cancer research; Immune checkpoint; Tumor-infiltrating lymphocytes; Estrogen receptor; Cancer; Immunology; Oncology; Internal medicine","authors":[{"name":"John Stagg","is_ca":true},{"name":"Bertrand Allard","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08073664781397404,"gpt":0.4189070756368191,"spread":0.3381704278228451,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.003639953,0.000334406,0.0009789347,0.0004188264,0.0001990806,0.00002496036,0.0006560711,0.0009670422,0.003022407],"category_scores_gemma":[0.0003405193,0.0002609461,0.00008761198,0.0007219404,0.003708111,0.0003946987,0.0001870147,0.002487939,0.0002514075],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003235998,"about_ca_system_score_gemma":0.0006352118,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009448673,"about_ca_topic_score_gemma":0.0009223635,"domain_scores_codex":[0.9938403,0.003066999,0.001117138,0.0006910473,0.000201918,0.0010826],"domain_scores_gemma":[0.9946838,0.004508894,0.0002056864,0.0003977135,0.0001253292,0.00007857406],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.003170977,0.001726546,0.04510212,0.00003647751,0.0002144105,0.00004316288,0.001467907,0.000003075439,0.002607839,0.002235908,0.00007179344,0.9433198],"study_design_scores_gemma":[0.0317127,0.00558733,0.773581,0.0007788901,0.00005501027,0.001143356,0.005386001,0.000447198,0.002355187,0.0360411,0.1417779,0.001134368],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7897102,0.191033,0.00005184122,0.01320843,0.001414469,0.002051843,0.00001212672,0.00008167535,0.002436436],"genre_scores_gemma":[0.9341289,0.0628072,0.00009406612,0.001143416,0.00008046558,0.000640267,0.000008901884,0.00003999268,0.00105682],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9421854,"threshold_uncertainty_score":0.9999843,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4379508645","doi":"10.1177/17588359231178125","title":"Rationale and trial design of NATALEE: a Phase III trial of adjuvant ribociclib + endocrine therapy <i>versus</i> endocrine therapy alone in patients with HR+/HER2− early breast cancer","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":99,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Genentech; PharmaMar; Novartis Institutes for BioMedical Research; Daewoong Pharmaceutical Company; Astellas Pharma; Eisai; Seagen; Mersana Therapeutics; Mylan; Syndax Pharmaceuticals; Clovis Oncology; Astex Pharmaceuticals; Merck KGaA; Taiho Pharmaceutical; F. Hoffmann-La Roche; Amgen; Radius Health; Daiichi Sankyo Europe; LEO Pharma; Gilead Sciences; Exelixis; Sanofi; Pfizer; Novartis Pharmaceuticals Corporation; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Medicine; Letrozole; Internal medicine; Breast cancer; Clinical endpoint; Oncology; Anastrozole; Palbociclib; Metastatic breast cancer; Goserelin; Randomization; Cancer; Adjuvant therapy; Clinical trial; Tamoxifen; Gynecology","authors":[{"name":"Dennis J. Slamon","is_ca":false},{"name":"Peter A. Fasching","is_ca":false},{"name":"Sara A. Hurvitz","is_ca":false},{"name":"Stephen Chia","is_ca":true},{"name":"John Crown","is_ca":false},{"name":"Miguel Martín","is_ca":false},{"name":"Carlos H. Barrios","is_ca":false},{"name":"Aditya Bardia","is_ca":false},{"name":"Seock‐Ah Im","is_ca":false},{"name":"Denise A. Yardley","is_ca":false},{"name":"Michael Untch","is_ca":false},{"name":"Chiun‐Sheng Huang","is_ca":false},{"name":"Daniil Stroyakovskiy","is_ca":false},{"name":"Binghe Xu","is_ca":false},{"name":"Rebecca Moroose","is_ca":false},{"name":"Sherene Loi","is_ca":false},{"name":"F. Visco","is_ca":false},{"name":"Valerie Bee-Munteanu","is_ca":false},{"name":"Karen Afenjar","is_ca":false},{"name":"Rodrigo Fresco","is_ca":false},{"name":"Tetiana Taran","is_ca":false},{"name":"Arunava Chakravartty","is_ca":false},{"name":"Juan Pablo Zarate","is_ca":false},{"name":"Agnes Lteif","is_ca":false},{"name":"Gabriel N. Hortobágyi","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0373529934834873,"gpt":0.3836976276393478,"spread":0.3463446341558605,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008249028,0.0004252307,0.001658713,0.0004234684,0.00005049731,0.000005214655,0.0003099437,0.0002044239,0.0005287065],"category_scores_gemma":[0.0001187148,0.0003113406,0.000104322,0.001059228,0.001117121,0.0003305318,0.00006786959,0.0005880766,0.000002245],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002576988,"about_ca_system_score_gemma":0.0009079584,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001680168,"about_ca_topic_score_gemma":0.0001519643,"domain_scores_codex":[0.9958051,0.0004989966,0.001236815,0.0006071044,0.001187426,0.0006645039],"domain_scores_gemma":[0.9970915,0.001466271,0.0005772582,0.0003942134,0.0002426967,0.0002280944],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.568946,0.002565065,0.002403034,0.00003627621,0.0002088671,0.00007326146,0.0005420698,0.00008733958,0.0004594721,0.0000765626,0.000006189832,0.4245959],"study_design_scores_gemma":[0.9492896,0.02887766,0.008946215,0.0002706157,0.00006929176,0.00003717082,0.0002623628,0.0002437464,0.0009863175,0.0006868613,0.01001485,0.000315296],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.980725,0.01008897,0.001059784,0.002196681,0.0008011831,0.004871085,0.000113436,0.0000717459,0.00007210241],"genre_scores_gemma":[0.9679568,0.02882211,0.0007962419,0.0007241347,0.0004101239,0.0010714,0.00008391463,0.00007604025,0.0000591705],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4242806,"threshold_uncertainty_score":0.9999338,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4391325299","doi":"10.1177/17588359231220511","title":"The role of aberrant DNA methylation in cancer initiation and clinical impacts","year":2024,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Epigenetics and DNA Methylation","field":"Biochemistry, Genetics and Molecular Biology","cited_by":91,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"National Health and Medical Research Council; National Cancer Institute; National Institutes of Health; Sierra Oncology; Swiss Cancer Research Foundation; Eisai; BeiGene; Clovis Oncology; AstraZeneca","keywords":"DNA methylation; Epigenetics; Methylation; Cancer research; DNA repair; Biology; Cancer epigenetics; MSH2; Context (archaeology); MLH1; DNA mismatch repair; Medicine; Genetics; Gene; Gene expression","authors":[{"name":"Franziska Geissler","is_ca":false},{"name":"Ksenija Nesic","is_ca":false},{"name":"Olga Kondrashova","is_ca":false},{"name":"Alexander Dobrovic","is_ca":false},{"name":"Elizabeth M. Swisher","is_ca":false},{"name":"Clare L. Scott","is_ca":false},{"name":"Matthew J. Wakefield","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02222546235469653,"gpt":0.4208826697653826,"spread":0.3986572074106861,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001486263,0.00007547583,0.0001618246,0.00004694037,0.00002298306,0.000006422415,0.00009474305,0.0002315084,0.00001756675],"category_scores_gemma":[0.0002669432,0.0000523286,0.00003332395,0.0001241611,0.0002287885,0.000008047384,0.00003867869,0.0001939035,7.439018e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003262118,"about_ca_system_score_gemma":0.000235387,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002731577,"about_ca_topic_score_gemma":0.001575747,"domain_scores_codex":[0.9987696,0.0003058417,0.0004293524,0.0001940462,0.0001492898,0.0001518172],"domain_scores_gemma":[0.9992759,0.0004654721,0.00007810289,0.0001002017,0.00002838819,0.00005197326],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001071726,0.00005590393,0.01456862,0.00001508294,0.0000194322,0.000002876007,0.0001147699,0.00004026542,0.02078411,0.00106473,0.000001583538,0.9632254],"study_design_scores_gemma":[0.002466133,0.002135672,0.1439239,0.0002465039,0.00006813018,0.000009493879,0.0005324536,0.01646689,0.0686502,0.07818844,0.6869758,0.0003364362],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7516824,0.2448303,0.00111002,0.0009113938,0.0003779659,0.0001379468,0.000002208947,0.000004228469,0.0009435251],"genre_scores_gemma":[0.8579026,0.1416942,0.00009202648,0.0001261783,0.0001401881,0.00002020356,0.000007828952,0.000007327902,0.0000094146],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.962889,"threshold_uncertainty_score":0.2133898,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3195679999","doi":"10.1177/17588359211035959","title":"The emerging role of molecular pathology in directing the systemic treatment of endometrial cancer","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":85,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Molecular pathology; Subtyping; Medicine; Endometrial cancer; Molecular diagnostics; Targeted therapy; Bioinformatics; Molecular marker; Cancer; Oncology; Internal medicine; Computational biology; Pathology; Biology; Gene; Genetics; Computer science","authors":[{"name":"Amy Jamieson","is_ca":true},{"name":"Tjalling Bosse","is_ca":false},{"name":"Jessica N. McAlpine","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04628385487803262,"gpt":0.4449737521368726,"spread":0.39868989725884,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001259407,0.0003666702,0.003677164,0.0003130707,0.00004961637,0.000003225914,0.0003793231,0.0004868003,0.000173398],"category_scores_gemma":[0.0009502001,0.0001712492,0.0005471846,0.001627534,0.0004853549,0.00002360196,0.00009164273,0.00058232,0.00000176862],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001047556,"about_ca_system_score_gemma":0.001575132,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002275623,"about_ca_topic_score_gemma":0.0003731487,"domain_scores_codex":[0.9951128,0.001732647,0.001646522,0.0004275269,0.0006104475,0.0004701072],"domain_scores_gemma":[0.9916553,0.006893193,0.0008152272,0.0004490236,0.00008210549,0.0001050853],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002986334,0.000487054,0.0002588115,0.001388923,0.0004663236,0.0004043231,0.0002716788,0.000006077404,0.00001682791,0.0003804915,3.44272e-7,0.9960205],"study_design_scores_gemma":[0.006184586,0.001699352,0.00002180416,0.009091485,0.001468612,0.0003852855,0.0007140947,0.00001338724,0.00009183413,0.000368622,0.9797969,0.0001639915],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0008008353,0.995626,0.00002211264,0.0003500645,0.001002989,0.001321165,0.00001237624,0.000009532317,0.0008549161],"genre_scores_gemma":[0.009430268,0.9891343,0.00004216508,0.00009780438,0.0003011337,0.0009122074,0.00001524374,0.00003467714,0.00003226504],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9958565,"threshold_uncertainty_score":0.6983341,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3202940729","doi":"10.1177/17588359211047352","title":"Metastatic Urothelial Cancer: a rapidly changing treatment landscape","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":66,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Metastatic Urothelial Carcinoma; Urothelial cancer; Immunotherapy; Clinical trial; Oncology; Chemotherapy; Disease; Cancer; Internal medicine; Intensive care medicine; Bladder cancer; Urothelial carcinoma","authors":[{"name":"Carlos Stecca","is_ca":true},{"name":"Osama Abdeljalil","is_ca":true},{"name":"Srikala S. Sridhar","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06794330522167166,"gpt":0.4500267465703506,"spread":0.382083441348679,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004798231,0.0007679282,0.00483596,0.0004957846,0.00008238496,0.00001366112,0.0002971462,0.0005945503,0.004923851],"category_scores_gemma":[0.00008913102,0.000506514,0.0007157379,0.0008755055,0.0002609236,0.00007910856,0.00008783837,0.0008119365,0.00008497536],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001473733,"about_ca_system_score_gemma":0.006274284,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005300783,"about_ca_topic_score_gemma":0.0002372774,"domain_scores_codex":[0.9957273,0.0007191384,0.00107451,0.0008509003,0.0007124457,0.0009157005],"domain_scores_gemma":[0.9978113,0.0008223364,0.0003574659,0.0005058432,0.00006138186,0.000441707],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001377094,0.0009267735,0.00003304159,0.003651912,0.001094007,0.002450047,0.0003057045,0.000001119648,1.453004e-7,0.0001757092,0.00003415394,0.9911897],"study_design_scores_gemma":[0.005128925,0.001786326,0.000001843911,0.01197247,0.003874581,0.0009701292,0.0001657682,0.00002837923,0.000002273966,0.00009589373,0.9756038,0.0003695694],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000005270002,0.991823,0.0002355877,0.0007403705,0.001353906,0.001702367,0.00007354908,0.00007709854,0.003988894],"genre_scores_gemma":[0.00002908967,0.9933809,0.0004107696,0.001517966,0.001098849,0.002190909,0.0001535148,0.0001208397,0.001097172],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9908201,"threshold_uncertainty_score":0.9997386,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2945349403","doi":"10.1177/1758835919850367","title":"Real-world comparative effectiveness of nab-paclitaxel plus gemcitabine <i>versus</i> FOLFIRINOX in advanced pancreatic cancer: a systematic review","year":2019,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Pancreatic and Hepatic Oncology Research","field":"Medicine","cited_by":64,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"Alberta Health Services","funders":"Celgene","keywords":"FOLFIRINOX; Medicine; Gemcitabine; Irinotecan; Internal medicine; Oxaliplatin; Neutropenia; Oncology; Pancreatic cancer; Gastroenterology; Cancer; Chemotherapy; Colorectal cancer","authors":[{"name":"E. Gabriela Chiorean","is_ca":false},{"name":"Winson Y. Cheung","is_ca":true},{"name":"Guido Giordano","is_ca":false},{"name":"George Kim","is_ca":false},{"name":"Salah‐Eddin Al‐Batran","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1137865024179143,"gpt":0.5148520294269145,"spread":0.4010655270090003,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","metaepi_broad","research_integrity"],"consensus_categories":[],"category_scores_codex":[0.006233881,0.001015711,0.02258932,0.0009368233,0.00004922141,0.000005620006,0.0009905145,0.001004184,0.0005371016],"category_scores_gemma":[0.001905364,0.0007104807,0.0007490254,0.002316033,0.001114172,0.0001775085,0.0002637916,0.002440526,0.0001017895],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.00439572,"about_ca_system_score_gemma":0.008114756,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003012265,"about_ca_topic_score_gemma":0.001455067,"domain_scores_codex":[0.9858143,0.006559344,0.003801572,0.001154771,0.001496647,0.001173385],"domain_scores_gemma":[0.9744994,0.0218392,0.001723178,0.001201457,0.0002873911,0.0004493847],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"systematic_review","study_design_scores_codex":[0.002151945,0.0006866721,0.000459267,0.8441633,0.001086124,0.0003811388,0.0001539869,0.000004855321,9.868287e-7,0.0008601652,0.00001695755,0.1500346],"study_design_scores_gemma":[0.01109516,0.002716854,0.000161041,0.8574945,0.009420834,0.0001419312,0.0001551242,0.0001563058,0.000001139176,0.0002166948,0.1178688,0.0005716743],"study_design_candidate":"systematic_review","study_design_consensus":"systematic_review","genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002272313,0.9747282,0.00007845595,0.0001986218,0.0007178463,0.01397448,0.00004002471,0.00004786048,0.009987243],"genre_scores_gemma":[0.0005258025,0.9913079,0.0003634924,0.0003959638,0.0001137265,0.006521532,0.0001246567,0.0000959329,0.0005509585],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.1494629,"threshold_uncertainty_score":0.9998609,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3001249325","doi":"10.1177/1758835919895756","title":"Targeting non-small cell lung cancer: driver mutation beyond epidermal growth factor mutation and anaplastic lymphoma kinase fusion","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":53,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"","keywords":"Anaplastic lymphoma kinase; Cancer research; ROS1; Epidermal growth factor receptor; Medicine; Mutation; Lung cancer; Anaplastic large-cell lymphoma; PI3K/AKT/mTOR pathway; ERBB3; Fusion gene; Protein kinase domain; Cancer; Lymphoma; Biology; Gene; Oncology; Signal transduction; Adenocarcinoma; Genetics; Immunology; Internal medicine","authors":[{"name":"Quincy S. Chu","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01754185532272969,"gpt":0.3809251556186141,"spread":0.3633833002958844,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0002335216,0.0005333476,0.001991994,0.0002702334,0.000135918,0.00001613246,0.0001739995,0.0006149288,0.0003410574],"category_scores_gemma":[0.0002210869,0.000406765,0.0001818177,0.0004552947,0.0002533121,0.0001738519,0.00008754366,0.0005856515,0.00001686288],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001305777,"about_ca_system_score_gemma":0.002472468,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007923249,"about_ca_topic_score_gemma":0.00009050827,"domain_scores_codex":[0.9969344,0.0003506556,0.0009862294,0.0007368574,0.0005004109,0.0004914643],"domain_scores_gemma":[0.9975937,0.001130274,0.000579389,0.000158762,0.0001099839,0.0004278847],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001169428,0.0002662014,0.0002368294,0.007146043,0.0002208208,0.002088942,0.001090338,0.00001240888,0.000003230655,0.00007794573,0.00003288602,0.9887074],"study_design_scores_gemma":[0.007248417,0.001564671,0.0003354853,0.006793054,0.00426423,0.0004991841,0.0003843027,0.003825124,0.000009400781,0.0002773537,0.9741959,0.0006028795],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0009568461,0.9911249,0.003783019,0.0007532045,0.0008549815,0.001799472,0.00005899177,0.00006017729,0.0006084636],"genre_scores_gemma":[0.005955652,0.9899852,0.001293011,0.001151745,0.0005004441,0.0005395826,0.0004351833,0.00007784426,0.00006128781],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9881045,"threshold_uncertainty_score":0.9998384,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4288013778","doi":"10.1177/17588359221112696","title":"The economic value of liquid biopsy for genomic profiling in advanced non-small cell lung cancer","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":51,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"Niagara Health System; University of Toronto; Princess Margaret Cancer Centre; Ottawa Hospital; University of British Columbia; University of Ottawa; Jewish General Hospital; McMaster University; Juravinski Cancer Centre; McGill University; University of Calgary","funders":"Jewish General Hospital; BC Cancer Foundation; Princess Margaret Cancer Foundation; Guardant Health; Ottawa Hospital Research Institute","keywords":"Liquid biopsy; Medicine; Lung cancer; Biopsy; Circulating tumor DNA; Cell-free fetal DNA; Lung; Oncology; Pathology; Cancer research; Internal medicine; Cancer; Biology; Genetics","authors":[{"name":"Doreen A. Ezeife","is_ca":true},{"name":"Eldon Spackman","is_ca":true},{"name":"Rosalyn A. Juergens","is_ca":true},{"name":"Janessa Laskin","is_ca":true},{"name":"Jason Agulnik","is_ca":true},{"name":"Desirée Hao","is_ca":true},{"name":"Scott A. Laurie","is_ca":true},{"name":"Jennifer Law","is_ca":true},{"name":"Lisa W. Le","is_ca":true},{"name":"Lesli A. Kiedrowski","is_ca":false},{"name":"Barbara Melosky","is_ca":true},{"name":"Frances A. Shepherd","is_ca":true},{"name":"Victor Cohen","is_ca":true},{"name":"Paul Wheatley‐Price","is_ca":true},{"name":"R Vandermeer","is_ca":true},{"name":"Janice J.N. Li","is_ca":true},{"name":"Roxanne Fernandes","is_ca":true},{"name":"Aria Shokoohi","is_ca":true},{"name":"Richard B. Lanman","is_ca":false},{"name":"Natasha B. Leighl","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.008545333577232495,"gpt":0.3190650196068914,"spread":0.310519686029659,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007916131,0.0001469227,0.0003054593,0.00005625005,0.0001073207,0.00000386845,0.000511774,0.0001321359,0.00004271985],"category_scores_gemma":[0.0000649463,0.000130291,0.00008232197,0.00008190808,0.0001817404,0.000003812251,0.0002437379,0.0002488163,5.256986e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004458618,"about_ca_system_score_gemma":0.001427257,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006758887,"about_ca_topic_score_gemma":0.0007807499,"domain_scores_codex":[0.9985287,0.0001223143,0.0005012975,0.0003526632,0.0001095541,0.000385523],"domain_scores_gemma":[0.9990189,0.0004182549,0.0002184768,0.0002519594,0.00002460162,0.0000678227],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01008026,0.0007299522,0.02420177,0.000329819,0.0001677522,0.00003860425,0.0009499539,0.2807542,0.3426321,0.007381156,0.0001766685,0.3325578],"study_design_scores_gemma":[0.01354164,0.006449115,0.001902543,0.00007337444,0.00009829859,0.00004498959,0.002433548,0.04770485,0.0970732,0.003564041,0.8262337,0.0008806407],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9507952,0.04400309,0.002196487,0.0006333831,0.001090715,0.0007644317,0.00006236918,0.00000382822,0.0004505086],"genre_scores_gemma":[0.9725225,0.02327438,0.001668572,0.0009652465,0.0002450116,0.001193226,0.00003802672,0.00003342477,0.00005958849],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.8260571,"threshold_uncertainty_score":0.5313115,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2787639107","doi":"10.1177/1758834017753338","title":"Turning <i>EGFR</i> mutation-positive non-small-cell lung cancer into a chronic disease: optimal sequential therapy with EGFR tyrosine kinase inhibitors","year":2018,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Royal Victoria Hospital","funders":"","keywords":"Osimertinib; Afatinib; Erlotinib; T790M; Gefitinib; Medicine; Lung cancer; Tolerability; Oncology; Epidermal growth factor receptor; Resistance mutation; Erlotinib Hydrochloride; Tyrosine kinase; Internal medicine; Cancer research; Cancer; Adverse effect; Biology; Receptor","authors":[{"name":"Vera Hirsh","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0187632283556493,"gpt":0.4154327985471971,"spread":0.3966695701915478,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003921209,0.000822022,0.002233685,0.0003318647,0.0002112954,0.00002951183,0.0003735055,0.0006069875,0.0007450487],"category_scores_gemma":[0.0000447819,0.0005453292,0.0003545335,0.00073641,0.0008890207,0.0002057144,0.00009502919,0.001158749,0.00002788826],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.004168615,"about_ca_system_score_gemma":0.01122561,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001811741,"about_ca_topic_score_gemma":0.0003914783,"domain_scores_codex":[0.9959675,0.0004148918,0.001035516,0.001016451,0.0007808041,0.0007848272],"domain_scores_gemma":[0.997436,0.0005661382,0.0006824233,0.0004582884,0.0002214889,0.0006356897],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007131051,0.000882659,0.0001247587,0.005770374,0.0009787729,0.001742103,0.001086626,0.00009645279,0.00000548786,0.00004390132,0.0001124155,0.9884433],"study_design_scores_gemma":[0.008598335,0.003220296,0.00003599906,0.02319677,0.004572718,0.0002084699,0.0001388114,0.0005323614,0.00003558253,0.00005840915,0.9587455,0.0006567627],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004797831,0.990311,0.003011556,0.0008537396,0.001117218,0.003126774,0.0000587326,0.00008082088,0.0009603242],"genre_scores_gemma":[0.001650373,0.9901529,0.001275384,0.001326833,0.002052082,0.002371692,0.0005819434,0.0001598255,0.0004289596],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9877866,"threshold_uncertainty_score":0.9996998,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3191554850","doi":"10.1177/17588359211036544","title":"IMbrave 151: a randomized phase II trial of atezolizumab combined with bevacizumab and chemotherapy in patients with advanced biliary tract cancer","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":47,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Roche (Canada)","funders":"","keywords":"Medicine; Atezolizumab; Bevacizumab; Gemcitabine; Clinical endpoint; Oncology; Chemotherapy; Internal medicine; Tumor microenvironment; Cancer; Immunotherapy; Clinical trial; Nivolumab","authors":[{"name":"Stephen P. Hack","is_ca":false},{"name":"Wendy Verret","is_ca":false},{"name":"Sohail Mulla","is_ca":true},{"name":"Bo Liu","is_ca":false},{"name":"Yulei Wang","is_ca":false},{"name":"Teresa Macarulla","is_ca":false},{"name":"Zhenggang Ren","is_ca":false},{"name":"Anthony B. El-Khoueiry","is_ca":false},{"name":"Andrew X. Zhu","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01165188480779092,"gpt":0.3378004446659155,"spread":0.3261485598581245,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004584745,0.0002964978,0.001912336,0.0001512483,0.00004996193,0.000003599078,0.0001128213,0.000191945,0.0002515432],"category_scores_gemma":[0.0001659335,0.0001882134,0.00009110259,0.0004433282,0.0008898517,0.0001255838,0.00005278041,0.0004759378,3.529044e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002235932,"about_ca_system_score_gemma":0.0009157901,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004594435,"about_ca_topic_score_gemma":0.000592226,"domain_scores_codex":[0.9974998,0.0003133359,0.0007090353,0.0004831827,0.0006003777,0.0003943205],"domain_scores_gemma":[0.9984328,0.0007097904,0.000264764,0.0002629648,0.0001659496,0.0001637324],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6220774,0.004059997,0.01193066,0.00009138121,0.0002247648,0.0001917111,0.001377425,0.000004339158,0.00002238007,0.0000760559,0.000004081866,0.3599398],"study_design_scores_gemma":[0.9512857,0.02172803,0.02162162,0.0004664159,0.0002364826,0.0000373351,0.0004484524,0.0001154456,0.0002218401,0.0003554779,0.003258452,0.0002247131],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9763733,0.01626422,0.0001121526,0.004477582,0.0002160126,0.001761143,0.000009855665,0.00002179536,0.000764006],"genre_scores_gemma":[0.9836195,0.01343597,0.0005465235,0.001839345,0.00007617744,0.0003782299,0.00002725543,0.00003223626,0.00004475678],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3597151,"threshold_uncertainty_score":0.767512,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2610105293","doi":"10.1177/1758834017704329","title":"Review of the use of pretest probability for molecular testing in non-small cell lung cancer and overview of new mutations that may affect clinical practice","year":2017,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":45,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical Practice; Affect (linguistics); Lung cancer; Medical physics; Oncology; Intensive care medicine; Family medicine; Psychology","authors":[{"name":"Petra Martin","is_ca":true},{"name":"Natasha B. Leighl","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.317195944797893,"gpt":0.5822947835792166,"spread":0.2650988387813236,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001728222,0.0002559639,0.002613661,0.00007176803,0.00002989455,0.000003037185,0.0002869283,0.0003423259,0.00002185922],"category_scores_gemma":[0.006777722,0.0001537211,0.0003264427,0.0002815134,0.0005500702,0.0001100611,0.00009847686,0.0005251776,1.351858e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002485017,"about_ca_system_score_gemma":0.00472752,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001944633,"about_ca_topic_score_gemma":0.0001966023,"domain_scores_codex":[0.9969187,0.0006838609,0.001492229,0.0003859581,0.0003005649,0.0002186465],"domain_scores_gemma":[0.9888418,0.008171008,0.002091577,0.0005594831,0.0002169189,0.0001192468],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004064393,0.0004403649,0.004019884,0.1458755,0.0001937679,0.00001000762,0.0000854301,0.000004348942,2.82273e-7,0.00007086736,0.00002161973,0.8492373],"study_design_scores_gemma":[0.001967921,0.0006562028,0.0007076293,0.2015734,0.005921803,0.00003743577,0.00001499707,0.00006481096,0.000002897317,0.0002443544,0.7886873,0.0001211588],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001097215,0.9923521,0.0004144876,0.0009995875,0.0002494717,0.005515835,0.00004607805,0.000004320347,0.0003083608],"genre_scores_gemma":[0.0001450832,0.9844007,0.01384426,0.0008429075,0.00004968745,0.0006328195,0.00002013243,0.00002648741,0.00003788971],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.8491161,"threshold_uncertainty_score":0.8386418,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3172779990","doi":"10.1177/17588359211019675","title":"Selpercatinib in RET fusion-positive non-small-cell lung cancer (SIREN): a retrospective analysis of patients treated through an access program","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":44,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Regional Municipality of Durham; Lakeridge Health; Queen's University; University of Manitoba; Research Institute in Oncology and Hematology; CancerCare Manitoba","funders":"Karl Landsteiner Privatuniversität für Gesundheitswissenschaften","keywords":"Medicine; Internal medicine; Brain metastasis; Lung cancer; Oncology; Adverse effect; Retrospective cohort study; Confidence interval; Population; Fusion gene; Cancer; Metastasis; Gene","authors":[{"name":"Oliver Illini","is_ca":false},{"name":"Maximilian J. Hochmair","is_ca":false},{"name":"Hannah Fabikan","is_ca":false},{"name":"Christoph Weinlinger","is_ca":false},{"name":"Amanda Tufman","is_ca":false},{"name":"Aurélie Swalduz","is_ca":false},{"name":"Kristina Lamberg","is_ca":false},{"name":"Sayed M.S. Hashemi","is_ca":false},{"name":"Florian Huemer","is_ca":false},{"name":"Anders Vikström","is_ca":false},{"name":"Martin Wermke","is_ca":false},{"name":"Gudrun Absenger","is_ca":false},{"name":"Alfredo Addeo","is_ca":false},{"name":"Shantanu Banerji","is_ca":true},{"name":"Antonio Calles","is_ca":false},{"name":"Stephen Clarke","is_ca":false},{"name":"Massimo Di Maïo","is_ca":false},{"name":"Alice Durand","is_ca":false},{"name":"M. Duruisseaux","is_ca":false},{"name":"Malinda Itchins","is_ca":false},{"name":"Okko-Sakari Kääränien","is_ca":false},{"name":"Florian Krenn","is_ca":false},{"name":"Eckart Laack","is_ca":false},{"name":"Adrianus J. de Langen","is_ca":false},{"name":"Katja Mohorčič","is_ca":false},{"name":"Georg Pall","is_ca":false},{"name":"Antonio Passaro","is_ca":false},{"name":"G. Prager","is_ca":false},{"name":"Achim Rittmeyer","is_ca":false},{"name":"J. Rothenstein","is_ca":true},{"name":"Michael A. Schumacher","is_ca":false},{"name":"Ewald Wöll","is_ca":false},{"name":"Arschang Valipour","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01930944574526549,"gpt":0.4443961404085657,"spread":0.4250866946633002,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000197996,0.0002153549,0.0009827344,0.0002423396,0.00004897046,0.000008207877,0.0001854636,0.0002590962,0.0008445082],"category_scores_gemma":[0.00007903297,0.000169541,0.0001230385,0.0021694,0.000228457,0.000269951,0.00007014615,0.0003773371,8.736714e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00107493,"about_ca_system_score_gemma":0.001138996,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006642138,"about_ca_topic_score_gemma":0.006528156,"domain_scores_codex":[0.9977747,0.0002722831,0.0006115414,0.0005368158,0.0004425074,0.0003621545],"domain_scores_gemma":[0.9987292,0.0002386954,0.0002387978,0.00029173,0.0003424393,0.0001591335],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004493848,0.005231598,0.7997174,0.00007438366,0.0008798231,0.0002125644,0.005434909,0.0001014177,0.00006918192,0.00009568971,0.000006995213,0.1877266],"study_design_scores_gemma":[0.008995027,0.002088816,0.9754816,0.0003004055,0.003156001,0.000004793971,0.001073107,0.005345423,0.000876024,0.0002928401,0.002164836,0.0002211247],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9856169,0.004548731,0.0003696743,0.00089959,0.000204072,0.00117203,0.00007267502,0.00003437091,0.007081989],"genre_scores_gemma":[0.9885898,0.007589452,0.001292893,0.00131026,0.00005409409,0.0005891241,0.0004649938,0.00002266219,0.00008678054],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1875055,"threshold_uncertainty_score":0.9246773,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2156077273","doi":"10.1177/1758834009358417","title":"Renal cell carcinoma bone metastases: clinical advances","year":2010,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Medical Imaging and Pathology Studies","field":"Medicine","cited_by":42,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Renal cell carcinoma; Zoledronic acid; Oncology; Systemic therapy; Targeted therapy; Bone disease; Clinical trial; Kidney cancer; Internal medicine; Cancer; Breast cancer; Osteoporosis","authors":[{"name":"Chakshu Sahi","is_ca":true},{"name":"Jennifer J. Knox","is_ca":true},{"name":"Mark Clemons","is_ca":true},{"name":"Anthony M. Joshua","is_ca":true},{"name":"Reuben Broom","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.04202467694925865,"gpt":0.4341992174272958,"spread":0.3921745404780371,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["sts","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00327514,0.0003068142,0.001298451,0.0001682651,0.0001058379,0.00000501936,0.0003324227,0.0005774294,0.0016388],"category_scores_gemma":[0.001857,0.0002194017,0.0001980293,0.0003133199,0.00283104,0.0001500751,0.000135923,0.002849379,0.0001273964],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00005429875,"about_ca_system_score_gemma":0.000643067,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001060977,"about_ca_topic_score_gemma":0.00020785,"domain_scores_codex":[0.9961675,0.0005966003,0.00113313,0.0006552913,0.0007302365,0.0007172469],"domain_scores_gemma":[0.9962357,0.00227512,0.0002463406,0.0004826609,0.0001041222,0.0006560982],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006014461,0.001367886,0.09937584,0.0001121474,0.00004282843,0.003051972,0.0002537215,9.912364e-7,0.0008260054,0.0008057081,0.0006983781,0.8928631],"study_design_scores_gemma":[0.006852282,0.002509442,0.01587889,0.00007331657,0.000209638,0.001109657,0.0003774995,0.0001875549,0.0004331988,0.003329797,0.9687591,0.0002795864],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7164997,0.1579883,0.00660733,0.03312726,0.008227886,0.001023737,0.00001686081,0.0002858823,0.07622304],"genre_scores_gemma":[0.9570547,0.01329339,0.01014067,0.01750854,0.001297474,0.00009505071,0.00002264919,0.0000353256,0.0005522289],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9680608,"threshold_uncertainty_score":0.9998827,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3199693232","doi":"10.1177/17588359211034708","title":"New approaches to first-line treatment of advanced renal cell carcinoma","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":39,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary","funders":"National Cancer Institute; Exelixis","keywords":"Axitinib; Medicine; Nivolumab; Pazopanib; Pembrolizumab; Cabozantinib; Sunitinib; Ipilimumab; Renal cell carcinoma; Oncology; Tyrosine-kinase inhibitor; Internal medicine; Avelumab; Kidney cancer; Lenvatinib; Immunotherapy; Cancer","authors":[{"name":"Daniel J. George","is_ca":false},{"name":"Chung‐Han Lee","is_ca":false},{"name":"Daniel Y.C. Heng","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1690109399906946,"gpt":0.3992702987299874,"spread":0.2302593587392927,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003545188,0.0008862527,0.005907214,0.0004422201,0.00004222023,0.000005570181,0.000424648,0.0009181509,0.0009834861],"category_scores_gemma":[0.0001000427,0.000606917,0.0008550144,0.0008633081,0.0002381769,0.00005887815,0.0001416731,0.000630167,0.00006266985],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002208371,"about_ca_system_score_gemma":0.004213655,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005119479,"about_ca_topic_score_gemma":0.0002112924,"domain_scores_codex":[0.9950089,0.0005102787,0.00173871,0.0010889,0.0008933981,0.0007598489],"domain_scores_gemma":[0.9961811,0.00131015,0.0005727444,0.0009533077,0.00005369657,0.0009289998],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0003489182,0.001811767,0.00004509933,0.004792706,0.0002289514,0.001958812,0.0003309512,0.00003378631,0.000001400315,0.0002069067,0.0000343729,0.9902063],"study_design_scores_gemma":[0.004638056,0.01034142,0.00002969532,0.005178426,0.00180103,0.000592011,0.00007810591,0.00001155592,0.0001441507,0.0001265523,0.9766561,0.0004028323],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002010071,0.9894588,0.001081285,0.001126961,0.0004980275,0.002471046,0.00001885833,0.00003634287,0.005107675],"genre_scores_gemma":[0.0008689153,0.9870364,0.008703782,0.0002628952,0.0005951831,0.0006225984,0.0002621104,0.0001115954,0.001536529],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9898035,"threshold_uncertainty_score":0.9999297,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4285189908","doi":"10.1177/17588359221108685","title":"Evolving landscape of first-line combination therapy in advanced renal cancer: a systematic review","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":37,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal; University of Calgary; Queen Elizabeth II Health Sciences Centre; McMaster University; Juravinski Cancer Centre","funders":"Pfizer Canada; Merck Canada; Ipsen; Eisai","keywords":"Medicine; Cancer therapy; Systematic review; Cancer; Kidney cancer; Oncology; MEDLINE; Intensive care medicine; Internal medicine","authors":[{"name":"Aly‐Khan A. Lalani","is_ca":true},{"name":"Daniel Y.C. Heng","is_ca":true},{"name":"Naveen S. Basappa","is_ca":false},{"name":"Lori Wood","is_ca":true},{"name":"Nayyer Iqbal","is_ca":false},{"name":"Deanna McLeod","is_ca":false},{"name":"Denis Soulières","is_ca":true},{"name":"Christian Kollmannsberger","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06161452145770124,"gpt":0.4158854827627571,"spread":0.3542709613050559,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002367828,0.0005885386,0.007201191,0.0005459319,0.00004550729,0.000003439918,0.0005509288,0.0004496421,0.002831529],"category_scores_gemma":[0.0008408513,0.0004023527,0.0005130731,0.001251127,0.0002001216,0.0001033279,0.0001238643,0.001349248,0.000008019097],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001900806,"about_ca_system_score_gemma":0.001517885,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003174801,"about_ca_topic_score_gemma":0.0002298344,"domain_scores_codex":[0.9933144,0.001598536,0.002724215,0.0006534113,0.001205883,0.0005034948],"domain_scores_gemma":[0.9946799,0.002884786,0.001489329,0.0006627668,0.00009334876,0.0001898445],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001095418,0.0006387136,0.00006033639,0.3896074,0.0001648845,0.0003534634,0.00006842961,0.000005667393,1.299461e-7,0.00004203963,0.000008633073,0.6089408],"study_design_scores_gemma":[0.003465685,0.002442453,0.00001389073,0.4623671,0.001359834,0.0003148309,0.00003954805,0.0001256996,8.540651e-7,0.0001389226,0.5294679,0.0002632183],"study_design_candidate":"systematic_review","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00003660112,0.9918914,0.00003981215,0.0005987637,0.0003760926,0.005797372,0.00001313362,0.00003369159,0.0012131],"genre_scores_gemma":[0.0003542606,0.9934705,0.0001098573,0.0008162138,0.0000752751,0.004810541,0.0001830502,0.00007535938,0.0001049536],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.6086776,"threshold_uncertainty_score":0.9998428,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3011081636","doi":"10.1177/1758835920911229","title":"Widespread expression of Sonic hedgehog (Shh) and Nrf2 in patients treated with cisplatin predicts outcome in resected tumors and are potential therapeutic targets for HPV-negative head and neck cancer","year":2020,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Hedgehog Signaling Pathway Studies","field":"Biochemistry, Genetics and Molecular Biology","cited_by":35,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Hospital for Sick Children; McGill University","funders":"","keywords":"Sonic hedgehog; Medicine; Cyclopamine; Cancer research; Clonogenic assay; Hedgehog; Cisplatin; Context (archaeology); Vismodegib; Cancer; Oncology; Head and neck squamous-cell carcinoma; Hedgehog signaling pathway; Head and neck cancer; Internal medicine; Chemotherapy; Cell; Biology; Signal transduction; Basal cell carcinoma","authors":[{"name":"Abu Shadat Mohammod Noman","is_ca":true},{"name":"Rashed R. Parag","is_ca":false},{"name":"Muhammad Rashid","is_ca":false},{"name":"Mohammad Zeshaan Rahman","is_ca":false},{"name":"Afrin Sultana","is_ca":false},{"name":"Chandsultana Jerin","is_ca":false},{"name":"Ayesha Siddiqua","is_ca":false},{"name":"Lutfur Rahman","is_ca":false},{"name":"Afsana Shirin","is_ca":false},{"name":"Junayed Nayeem","is_ca":false},{"name":"Reaz Mahmud","is_ca":false},{"name":"Sonam Akther","is_ca":false},{"name":"Rajib Shil","is_ca":false},{"name":"Ikram Hossain","is_ca":false},{"name":"Arfina Chowdhury","is_ca":false},{"name":"Shabnam B. Basher","is_ca":false},{"name":"Abul Hasan","is_ca":false},{"name":"Shammy Bithy","is_ca":false},{"name":"Jannatul Aklima","is_ca":false},{"name":"Mizanur Rahman","is_ca":false},{"name":"Nabila Chowdhury","is_ca":false},{"name":"Tahmina Banu","is_ca":false},{"name":"Bedri Karakas","is_ca":false},{"name":"Herman Yeger","is_ca":true},{"name":"Walid A. Farhat","is_ca":false},{"name":"Syed S. Islam","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02253777044378503,"gpt":0.3312867025453674,"spread":0.3087489321015823,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002758647,0.000227076,0.0005923352,0.00007979889,0.00004099367,0.000004225816,0.0001148449,0.0002491662,0.000008587917],"category_scores_gemma":[0.0004005396,0.000173629,0.00002256232,0.0001670364,0.0004894989,0.00001826823,0.0001134337,0.0002437555,8.053765e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000046397,"about_ca_system_score_gemma":0.0001110623,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003899405,"about_ca_topic_score_gemma":0.0006173091,"domain_scores_codex":[0.9982569,0.0002606278,0.0004751186,0.0004498201,0.0001995089,0.0003580804],"domain_scores_gemma":[0.9992266,0.0002546829,0.0002059113,0.0001007183,0.00006725224,0.0001447824],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.004729942,0.0002827623,0.9290184,0.0002438884,0.00005697112,0.00002088244,0.001718868,0.0001208922,0.01569463,0.00001056279,0.000006541291,0.04809565],"study_design_scores_gemma":[0.020239,0.007466014,0.9404462,0.0007309411,0.00006072963,0.00000892938,0.001239341,0.001746007,0.02632639,0.0003621609,0.0009217079,0.000452592],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9800768,0.01826136,0.0003836256,0.0005030118,0.0000538719,0.0006604742,0.0000308467,0.00000812144,0.00002184271],"genre_scores_gemma":[0.9958988,0.002758209,0.0004249284,0.0006767644,0.00005117956,0.0001398571,0.00002166883,0.0000236357,0.00000492054],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.04764306,"threshold_uncertainty_score":0.7080384,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3009738710","doi":"10.1177/1758835920915299","title":"Second-line treatment in patients with advanced extra-pulmonary poorly differentiated neuroendocrine carcinoma: a systematic review and meta-analysis","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Neuroendocrine Tumor Research Advances","field":"Medicine","cited_by":35,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Servier; Ipsen Fund; NuCana","keywords":"Medicine; Internal medicine; Everolimus; Progression-free survival; Oncology; Prospective cohort study; Sample size determination; Chemotherapy","authors":[{"name":"Mairéad G. McNamara","is_ca":false},{"name":"Melissa Frizziero","is_ca":false},{"name":"Timothy W. Jacobs","is_ca":false},{"name":"Ángela Lamarca","is_ca":false},{"name":"Richard Hubner","is_ca":false},{"name":"Juan W. Valle","is_ca":false},{"name":"Eitan Amir","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05922102353235283,"gpt":0.4006608372262131,"spread":0.3414398136938603,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","metaepi_broad","insufficient_payload"],"consensus_categories":["metaepi_narrow"],"category_scores_codex":[0.0003606937,0.001294784,0.01893581,0.0009477764,0.0000522766,0.00001523035,0.0006022308,0.00009457268,0.00132758],"category_scores_gemma":[0.0005545986,0.0007240198,0.001242421,0.002507986,0.0004880579,0.0002246814,0.0002200232,0.001657519,0.00002036187],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007347482,"about_ca_system_score_gemma":0.000816455,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001474965,"about_ca_topic_score_gemma":0.0002930028,"domain_scores_codex":[0.9908424,0.002513313,0.002689619,0.001594531,0.001300965,0.001059183],"domain_scores_gemma":[0.9952111,0.001821142,0.001048694,0.0009904357,0.0001341643,0.0007945012],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"systematic_review","study_design_gemma":"meta_analysis","study_design_scores_codex":[0.000667627,0.002608495,0.0003638288,0.6759689,0.03168449,0.03115949,0.00002596363,0.000002016998,1.104779e-7,0.00002573072,0.000003206198,0.2574902],"study_design_scores_gemma":[0.006226262,0.008947062,0.0002160264,0.02173706,0.7165577,0.002529271,0.00002877221,0.00005104801,8.147788e-7,0.00005168147,0.2427687,0.0008855685],"study_design_candidate":"meta_analysis","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001112544,0.9883556,0.00002272826,0.001385463,0.00006090869,0.009717175,0.0001074424,0.00007112848,0.0001683098],"genre_scores_gemma":[0.003680539,0.9896366,0.0001908618,0.002134627,0.00003606851,0.003578828,0.0003378125,0.0001329338,0.0002717443],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.6848732,"threshold_uncertainty_score":0.9999804,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4205813526","doi":"10.1177/17588359211066677","title":"Current and future landscape of targeted therapy in HER2-positive advanced breast cancer: redrawing the lines","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":28,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Mount Sinai Hospital; University of Calgary; Université Laval; Queen Elizabeth II Health Sciences Centre; University of Alberta; University of Toronto; Dalhousie University; University of British Columbia; BC Cancer Agency","funders":"F. Hoffmann-La Roche; AstraZeneca; Mylan; Pfizer","keywords":"Medicine; Trastuzumab; Neratinib; Oncology; Capecitabine; Internal medicine; Breast cancer; Hazard ratio; Clinical trial; Metastatic breast cancer; Cancer; Progression-free survival; Overall survival; Confidence interval; Colorectal cancer","authors":[{"name":"Christine Simmons","is_ca":true},{"name":"Daniel Rayson","is_ca":true},{"name":"Anil A. Joy","is_ca":true},{"name":"Jan‐Willem Henning","is_ca":true},{"name":"Julie Lemieux","is_ca":true},{"name":"Heather L. McArthur","is_ca":false},{"name":"Paul Card","is_ca":false},{"name":"Rebecca Dent","is_ca":false},{"name":"Christine Brezden‐Masley","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05377138215085864,"gpt":0.4747381370782596,"spread":0.420966754927401,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002064392,0.0005330665,0.002960226,0.0004339548,0.00009538966,0.000008070926,0.0007205194,0.0005535769,0.002589833],"category_scores_gemma":[0.0001475793,0.0003230261,0.0002541678,0.001396302,0.000832185,0.0000922792,0.0002651295,0.00351312,0.000002659887],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008208654,"about_ca_system_score_gemma":0.003330751,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007537144,"about_ca_topic_score_gemma":0.0002997642,"domain_scores_codex":[0.9942975,0.001702996,0.001300852,0.0007543794,0.001220822,0.0007234372],"domain_scores_gemma":[0.9966825,0.001924986,0.0005179649,0.0005304267,0.0001002741,0.0002438894],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006390557,0.000437394,0.000664869,0.003933098,0.0001329482,0.0001824082,0.0006514434,0.000003884583,0.0000010681,0.0001051059,0.00004243674,0.9932063],"study_design_scores_gemma":[0.002482198,0.0009977864,0.0006097439,0.007690889,0.0001501441,0.0003782237,0.0005722809,0.00005377455,0.000001209777,0.0001738635,0.9866175,0.0002723619],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001782786,0.9905878,0.000009665972,0.005139107,0.001378048,0.002079253,0.00009825947,0.00002846283,0.0005010656],"genre_scores_gemma":[0.0003421452,0.9961335,0.00007811446,0.0007354954,0.001183982,0.00133829,0.00008217014,0.00008319227,0.00002309159],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9929339,"threshold_uncertainty_score":0.9999222,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4323024632","doi":"10.1177/17588359231157644","title":"Fighting resistance: post-PARP inhibitor treatment strategies in ovarian cancer","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":27,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; PARP inhibitor; Ovarian cancer; Oncology; Cancer research; Poly ADP ribose polymerase; Internal medicine; Cancer; Pharmacology; DNA; Biology; Genetics","authors":[{"name":"Ana Veneziani","is_ca":true},{"name":"Clare L. Scott","is_ca":false},{"name":"Matthew J. Wakefield","is_ca":false},{"name":"Anna V. Tinker","is_ca":true},{"name":"Stéphanie Lheureux","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09070451031767579,"gpt":0.4848637584573334,"spread":0.3941592481396576,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","research_integrity","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001134455,0.0008205086,0.00418085,0.0007790268,0.00008191681,0.00002301825,0.0004496745,0.001404621,0.001608292],"category_scores_gemma":[0.0002208978,0.0006102442,0.0004337929,0.001427024,0.000600933,0.0002148195,0.0000818167,0.00171051,0.0001437284],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.00490559,"about_ca_system_score_gemma":0.008329125,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001654111,"about_ca_topic_score_gemma":0.006316076,"domain_scores_codex":[0.9939951,0.0009140983,0.002084737,0.00105663,0.0009179124,0.001031562],"domain_scores_gemma":[0.9962099,0.002034224,0.0006877125,0.0005981009,0.0001090409,0.0003610083],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0004770693,0.0003864677,0.0000196565,0.006628487,0.0002535174,0.001712908,0.0005262682,0.000008037991,0.000004811979,0.001385046,0.00008308831,0.9885147],"study_design_scores_gemma":[0.004848033,0.0008226239,0.00002025118,0.03807151,0.000365372,0.0001181339,0.0004796734,0.00001025382,0.000006492698,0.002517454,0.9522613,0.0004789309],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00002578985,0.9871085,0.00009514343,0.00270991,0.001787865,0.002013551,0.00008262711,0.0001614935,0.006015175],"genre_scores_gemma":[0.00006857803,0.9917409,0.0004447415,0.00153375,0.001577336,0.003060272,0.0001723941,0.0001651995,0.001236769],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9880357,"threshold_uncertainty_score":0.9998918,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2945903793","doi":"10.1177/1758835919846372","title":"FAM84B promotes prostate tumorigenesis through a network alteration","year":2019,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"St. Joseph’s Healthcare Hamilton; McMaster University; St. Joseph's Hospital","funders":"Cancer Research Society","keywords":"DU145; Cancer research; Carcinogenesis; Prostate cancer; Cell growth; Biology; Metastasis; Cell cycle; Cell; Cancer; Medicine; Genetics; LNCaP","authors":[{"name":"Yanzhi Jiang","is_ca":true},{"name":"Xiaozeng Lin","is_ca":true},{"name":"Anil Kapoor","is_ca":true},{"name":"Lizhi He","is_ca":false},{"name":"Fengxiang Wei","is_ca":false},{"name":"Yan Gu","is_ca":true},{"name":"Wenjuan Mei","is_ca":true},{"name":"Kuncheng Zhao","is_ca":true},{"name":"Huixiang Yang","is_ca":false},{"name":"Damu Tang","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02679852681546533,"gpt":0.3997595675188897,"spread":0.3729610407034244,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006089275,0.0001812971,0.0005357616,0.00006357073,0.00005695619,0.000008677103,0.0001509503,0.0001988952,0.001298452],"category_scores_gemma":[0.00006531684,0.0001241502,0.00006456911,0.000379104,0.0002606335,0.0002081473,0.000055413,0.0004470267,0.0001779803],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003345839,"about_ca_system_score_gemma":0.0006944732,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001832991,"about_ca_topic_score_gemma":0.0000465178,"domain_scores_codex":[0.9978375,0.0002108806,0.0003968633,0.0003857158,0.0005774491,0.0005915478],"domain_scores_gemma":[0.9990945,0.0003335501,0.00009155299,0.0002466537,0.00007160975,0.0001621409],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003830482,0.001045999,0.09870948,0.0003551605,0.0001592482,0.0007269139,0.001969573,0.0001616443,0.00100633,0.004382506,0.0002311717,0.8874215],"study_design_scores_gemma":[0.01806067,0.008863603,0.01648001,0.00086045,0.0001243133,0.0003563905,0.0006850137,0.004914311,0.003076345,0.04416874,0.9018919,0.0005183056],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8429811,0.0827826,0.003080984,0.02607289,0.002444129,0.00489608,0.000007141369,0.0002329946,0.03750209],"genre_scores_gemma":[0.9707373,0.01963469,0.002102382,0.00435656,0.000582279,0.0003042434,0.00005893338,0.00003767611,0.002185965],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9016607,"threshold_uncertainty_score":0.9996145,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3139304883","doi":"10.1177/1758835921998586","title":"Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":24,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal","funders":"Myovant Sciences","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Adverse effect; Testosterone (patch); Management of prostate cancer; Internal medicine; Oncology; Gonadotropin-releasing hormone; Androgen; Androgen suppression; Cancer; Luteinizing hormone; Endocrinology; Hormone","authors":[{"name":"Fred Saad","is_ca":true},{"name":"Neal D. Shore","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0585975078822475,"gpt":0.4545254438389683,"spread":0.3959279359567208,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004025759,0.0003976905,0.002211435,0.000206464,0.00004488718,0.00000481366,0.000253634,0.000368908,0.0001550222],"category_scores_gemma":[0.00003214369,0.0002411773,0.000222939,0.0006141696,0.0003318237,0.00009221181,0.00007442054,0.0004642892,0.000001371722],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006498981,"about_ca_system_score_gemma":0.001568924,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000004524391,"about_ca_topic_score_gemma":0.00001457246,"domain_scores_codex":[0.9971644,0.0001368249,0.0008254837,0.0006102948,0.0007511342,0.0005119002],"domain_scores_gemma":[0.9983379,0.000395605,0.0004652023,0.0003653911,0.000262914,0.0001730133],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.002289309,0.001361656,0.0004965016,0.01048781,0.0008947979,0.00006989729,0.00008713968,0.000004489492,3.782742e-7,0.0002852547,0.00001370836,0.984009],"study_design_scores_gemma":[0.01511047,0.00214783,0.0001680216,0.01640404,0.0005846873,0.00001107773,0.00006208831,0.00001154931,0.000009913665,0.0001136228,0.9651487,0.0002280414],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003756005,0.9926577,0.0005694967,0.0003771034,0.0002148443,0.005418974,0.0000913971,0.00002230737,0.0002725775],"genre_scores_gemma":[0.00009339426,0.9918833,0.002898432,0.000293368,0.00007443004,0.003824704,0.0006298564,0.00007516424,0.0002273885],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.983781,"threshold_uncertainty_score":0.9834926,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3010740851","doi":"10.1177/1758835920909091","title":"Positive progress: current and evolving role of immune checkpoint inhibitors in metastatic triple-negative breast cancer","year":2020,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Alberta Cancer Foundation; Mount Sinai Hospital; Dr. H. Bliss Murphy Cancer Centre; BC Cancer Agency","funders":"","keywords":"Atezolizumab; Medicine; Metastatic breast cancer; Pembrolizumab; Oncology; Internal medicine; Hazard ratio; Triple-negative breast cancer; Breast cancer; Population; Chemotherapy; Placebo; Progression-free survival; Clinical trial; Cancer; Immunotherapy; Confidence interval; Pathology","authors":[{"name":"Christine Simmons","is_ca":true},{"name":"Christine Brezden‐Masley","is_ca":true},{"name":"Joy McCarthy","is_ca":true},{"name":"Deanna McLeod","is_ca":false},{"name":"Anil A. Joy","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02692938279819948,"gpt":0.4086304143515668,"spread":0.3817010315533673,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001046296,0.0005152082,0.003608119,0.0003784953,0.00003105072,0.00000682104,0.0002660201,0.0003753818,0.0003892004],"category_scores_gemma":[0.0002101661,0.0003688678,0.0003926262,0.0009398345,0.001212872,0.0001322649,0.0001303531,0.001419648,0.000002683095],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001030149,"about_ca_system_score_gemma":0.002428175,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001721389,"about_ca_topic_score_gemma":0.0002106698,"domain_scores_codex":[0.9956272,0.0007438915,0.001974218,0.0005993851,0.0005839043,0.0004714543],"domain_scores_gemma":[0.9975925,0.0009225386,0.0009650858,0.0002149099,0.00009021763,0.0002147608],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00150376,0.0005208394,0.0002053587,0.006517102,0.0004509643,0.0001451299,0.001073852,1.31694e-7,0.000009561583,0.00003923245,0.000003336061,0.9895307],"study_design_scores_gemma":[0.008233334,0.001548862,0.001305107,0.06308019,0.001273001,0.0006181372,0.0009503334,0.0001577631,0.00004091601,0.0006805588,0.9215772,0.0005345956],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001000326,0.9958026,0.00002017268,0.001254274,0.0005337702,0.002004617,0.00007969148,0.00002062447,0.0001842259],"genre_scores_gemma":[0.002564153,0.9960965,0.000252773,0.0002024796,0.0002051614,0.0005865021,0.00003246878,0.00005254876,0.000007436124],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9889961,"threshold_uncertainty_score":0.9998763,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4409528322","doi":"10.1177/17588359251327992","title":"TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Foundation Medicine; Chugai Pharmaceutical; Samsung; Aptitude Health; Astellas Pharma; Eisai; Relay Therapeutics; Seagen; Silverback Therapeutics; Daewoong Pharmaceutical Company; AstraZeneca España; Puma Biotechnology; Genentech; Veracyte; Mersana Therapeutics; Menarini Silicon Biosystems; Daiichi Sankyo Europe; Gilead Sciences; Sanofi; Amgen; Pfizer; HCA Healthcare; Les Laboratories Pierre Fabre; G1 Therapeutics; Celgene; Carrick Therapeutics; AstraZeneca; Eli Lilly and Company; GlaxoSmithKline","keywords":"Medicine; Pembrolizumab; Durvalumab; Gemcitabine; Clinical endpoint; Internal medicine; Oncology; Carboplatin; Chemotherapy; Clinical trial; Cancer; Immunotherapy; Cisplatin","authors":[{"name":"Peter Schmid","is_ca":false},{"name":"Mafalda Oliveira","is_ca":false},{"name":"Joyce O’Shaughnessy","is_ca":false},{"name":"Massimo Cristofanilli","is_ca":false},{"name":"Stephanie L. Graff","is_ca":false},{"name":"Seock-Ah Im","is_ca":false},{"name":"Sherene Loi","is_ca":false},{"name":"Shigehira Saji","is_ca":false},{"name":"Shusen Wang","is_ca":false},{"name":"David W. Cescon","is_ca":true},{"name":"Tina Hovey","is_ca":false},{"name":"Agata Nawrot","is_ca":false},{"name":"KY Tse","is_ca":false},{"name":"Petra Vuković","is_ca":false},{"name":"Giuseppe Curigliano","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03195292858781053,"gpt":0.4375393702416746,"spread":0.405586441653864,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001754386,0.0005712779,0.003454539,0.0006037645,0.00009170658,0.0000152695,0.0005811885,0.0002320495,0.002413876],"category_scores_gemma":[0.0006017924,0.0003093073,0.00009072282,0.001937135,0.001544417,0.0002314992,0.0001129563,0.001307926,0.000003431759],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002055371,"about_ca_system_score_gemma":0.008274933,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002168591,"about_ca_topic_score_gemma":0.01546922,"domain_scores_codex":[0.992877,0.001891539,0.001518946,0.0009169558,0.001900001,0.0008955742],"domain_scores_gemma":[0.9952764,0.002699392,0.0004925244,0.000636412,0.0005379254,0.0003573463],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7128524,0.008599777,0.006803533,0.0002867294,0.00100785,0.0002279644,0.002670113,0.0001389764,0.00000275156,0.00005858612,0.00001866404,0.2673327],"study_design_scores_gemma":[0.9510641,0.03041961,0.005763474,0.001955549,0.0006645918,0.00004640246,0.003773734,0.004616681,0.00004140269,0.0001113405,0.001172719,0.0003704306],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814369,0.001982268,0.002463116,0.002405763,0.0006248378,0.01037361,0.00005618976,0.00005862646,0.0005986894],"genre_scores_gemma":[0.9916603,0.003212583,0.001014346,0.001075816,0.00007546773,0.00251456,0.00002778434,0.00007048679,0.0003486375],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2669623,"threshold_uncertainty_score":0.9999359,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2113562909","doi":"10.1177/1758834009352498","title":"Review: Targeted therapy for metastatic renal cell carcinoma: current treatment and future directions","year":2009,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Calgary; BC Cancer Agency","funders":"","keywords":"Temsirolimus; Pazopanib; Medicine; Axitinib; Sorafenib; Sunitinib; Bevacizumab; Everolimus; Renal cell carcinoma; Targeted therapy; Oncology; PI3K/AKT/mTOR pathway; Adjuvant; Clinical trial; Vascular endothelial growth factor; Adjuvant therapy; Internal medicine; Pharmacology; Discovery and development of mTOR inhibitors; Cancer; VEGF receptors; Chemotherapy","authors":[{"name":"Daniel Y.C. Heng","is_ca":true},{"name":"Christian Kollmannsberger","is_ca":true},{"name":"Kim N.","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03495072061428077,"gpt":0.3814300607698013,"spread":0.3464793401555206,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003998091,0.0003213703,0.0009271504,0.0001332361,0.00008278635,0.000004482862,0.0001051048,0.0001293841,0.0002158931],"category_scores_gemma":[0.00004022072,0.0002076267,0.0001704349,0.0002595076,0.0001757481,0.00007492522,0.00001206857,0.0002999002,0.000005924683],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004986499,"about_ca_system_score_gemma":0.0004259961,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000007846477,"about_ca_topic_score_gemma":0.00002442158,"domain_scores_codex":[0.9980205,0.0002524001,0.0005392663,0.0004680272,0.0002810715,0.0004386991],"domain_scores_gemma":[0.9987644,0.0003986682,0.0001524001,0.0002809569,0.00007590589,0.0003276781],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007553964,0.001764819,0.0004855418,0.0002227579,0.00004795294,0.00009312064,0.0002578667,6.909162e-7,0.0002610749,0.0001598066,0.0002498727,0.9957011],"study_design_scores_gemma":[0.008948921,0.01030371,0.006513787,0.0002266696,0.000338051,0.0002296168,0.00008302756,0.00009129778,0.0008487034,0.001223553,0.9710056,0.0001871046],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.04824978,0.9327261,0.0004165066,0.01483328,0.0004760323,0.002073356,0.000009851354,0.00004859193,0.001166447],"genre_scores_gemma":[0.2354593,0.7554459,0.002037865,0.005857137,0.0005207596,0.0004963389,0.00006630509,0.00002273411,0.00009362937],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.995514,"threshold_uncertainty_score":0.846677,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4296502312","doi":"10.1177/17588359221126151","title":"Plasma-first: accelerating lung cancer diagnosis and molecular profiling through liquid biopsy","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":22,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University Health Network","funders":"","keywords":"Medicine; Cohort; Lung cancer; Internal medicine; Biopsy; Referral; Liquid biopsy; Cancer; Oncology; Clinical endpoint; Cohort study; Pathology; Clinical trial","authors":[{"name":"Miguel García-Pardo","is_ca":true},{"name":"Kasia Czarnecka","is_ca":true},{"name":"Jennifer Law","is_ca":true},{"name":"Alexandra Salvarrey","is_ca":true},{"name":"Roxanne Fernandes","is_ca":true},{"name":"Jason Fan","is_ca":true},{"name":"Lucy Corke","is_ca":true},{"name":"Thomas K. Waddell","is_ca":true},{"name":"Kazuhiro Yasufuku","is_ca":true},{"name":"Laura Donahoe","is_ca":true},{"name":"Andrew Pierre","is_ca":true},{"name":"Lisa W. Le","is_ca":true},{"name":"Noor Ghumman","is_ca":true},{"name":"Geoffrey Liu","is_ca":true},{"name":"Frances A. Shepherd","is_ca":true},{"name":"Penelope A. Bradbury","is_ca":true},{"name":"Adrian G. Sacher","is_ca":true},{"name":"Tracy Stockley","is_ca":true},{"name":"Prodipto Pal","is_ca":true},{"name":"Patrik Rogalla","is_ca":true},{"name":"Ming‐Sound Tsao","is_ca":true},{"name":"Natasha B. Leighl","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01814273573074241,"gpt":0.3462831243431265,"spread":0.3281403886123841,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003915029,0.0001885482,0.0002958196,0.00004589629,0.0002054276,0.00001164213,0.0003100869,0.0001743579,0.0003541777],"category_scores_gemma":[0.0001721122,0.0001906945,0.00005358694,0.0001654997,0.000220319,0.000009805034,0.0004616184,0.0003778823,7.197176e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001638347,"about_ca_system_score_gemma":0.0003809468,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00006653238,"about_ca_topic_score_gemma":0.00025697,"domain_scores_codex":[0.998333,0.0001567316,0.0003556001,0.0004808689,0.000277068,0.0003966734],"domain_scores_gemma":[0.999297,0.0002199945,0.0001297638,0.0002080892,0.00003166271,0.0001135372],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.004286197,0.002013854,0.1284698,0.0005341567,0.0006405335,0.001297149,0.002982898,0.02428403,0.08285828,0.02448141,0.00132356,0.7268281],"study_design_scores_gemma":[0.003909399,0.002545763,0.0002918262,0.00006862947,0.00008842054,0.0002128436,0.0008040438,0.005960148,0.04037714,0.001571649,0.9434934,0.0006767252],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8917453,0.09936804,0.002629359,0.003675554,0.000808294,0.0004322519,0.00004352301,0.0000177881,0.001279844],"genre_scores_gemma":[0.9411141,0.04848601,0.00228417,0.006058458,0.0002971484,0.001660216,0.00004443769,0.00003725642,0.0000182416],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9421698,"threshold_uncertainty_score":0.7776295,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2166720958","doi":"10.1177/1758834011399306","title":"Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes","year":2011,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Tolerability; Lung cancer; Regimen; Oncology; Maintenance therapy; Intensive care medicine; Chemotherapy; Immunotherapy; Disease; Internal medicine; Clinical trial; Cancer; Adverse effect","authors":[{"name":"Linda Coate","is_ca":true},{"name":"Frances A. Shepherd","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01875366617280496,"gpt":0.3790955163536733,"spread":0.3603418501808683,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004014038,0.0002253813,0.0006875548,0.0001285933,0.00005016926,0.000002843882,0.0001513951,0.0002103821,0.0004321398],"category_scores_gemma":[0.00006707959,0.0001614385,0.00005939568,0.000272733,0.0003415484,0.0001695422,0.0000385928,0.0004079154,0.000003668282],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007511539,"about_ca_system_score_gemma":0.0007881748,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004766971,"about_ca_topic_score_gemma":0.001631379,"domain_scores_codex":[0.9982033,0.0001213979,0.0005305242,0.0004499253,0.0002407408,0.00045408],"domain_scores_gemma":[0.9990858,0.0002433688,0.0001327304,0.0002593971,0.00007331492,0.0002054343],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0004591818,0.0007867748,0.6659231,0.000065077,0.00004151719,0.0000872191,0.002151443,0.00001242695,0.00004619376,0.0005401669,0.000006875897,0.3298801],"study_design_scores_gemma":[0.01459488,0.001311981,0.960745,0.0002398575,0.00008734517,0.00003313498,0.0010857,0.0007739674,0.0001426236,0.004340821,0.01639463,0.0002500553],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9391897,0.04108622,0.002474214,0.00306659,0.0005660006,0.001276862,0.000006490472,0.00004875792,0.01228512],"genre_scores_gemma":[0.9688655,0.02522171,0.002273026,0.002860295,0.00004714405,0.0004866267,0.000004570964,0.00002163887,0.0002194741],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.32963,"threshold_uncertainty_score":0.6583273,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4407230737","doi":"10.1177/17588359251316176","title":"TROPION-Breast04: a randomized phase III study of neoadjuvant datopotamab deruxtecan (Dato-DXd) plus durvalumab followed by adjuvant durvalumab versus standard of care in patients with treatment-naïve early-stage triple negative or HR-low/HER2− breast cancer","year":2025,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University Health Centre","funders":"Genentech; Astellas Pharma; Daiichi-Sankyo; Natera; Puma Biotechnology; Syndax Pharmaceuticals; Chugai Pharmaceutical; Nihon Medi-Physics; Eisai; Jazz Pharmaceuticals; Incyte; Taiho Pharmaceutical; Spectrum Pharmaceuticals; Boston Scientific Corporation; Gilead Sciences; Exelixis; Sanofi; Amgen; Pfizer; Celgene; AstraZeneca; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Durvalumab; Medicine; Pembrolizumab; Internal medicine; Breast cancer; Chemotherapy; Clinical endpoint; Oncology; Adjuvant; Triple-negative breast cancer; Cancer; Clinical trial; Immunotherapy","authors":[{"name":"Heather L. McArthur","is_ca":false},{"name":"Sara M. Tolaney","is_ca":false},{"name":"Rebecca Dent","is_ca":false},{"name":"Peter Schmid","is_ca":false},{"name":"Jamil Asselah","is_ca":true},{"name":"Qiang Liu","is_ca":false},{"name":"Jane Meisel","is_ca":false},{"name":"Naoki Niikura","is_ca":false},{"name":"Gustavo Werutsky","is_ca":false},{"name":"Giampaolo Bianchini","is_ca":false},{"name":"Jay C. Andersen","is_ca":false},{"name":"Robert Kozarski","is_ca":false},{"name":"Nana Rokutanda","is_ca":false},{"name":"Barbara Pistilli","is_ca":false},{"name":"Sibylle Loibl","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01792386089167593,"gpt":0.4126227275079166,"spread":0.3946988666162407,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001042743,0.0006281533,0.004174369,0.000581733,0.0001001607,0.00001161962,0.0005845389,0.0003989621,0.001128817],"category_scores_gemma":[0.0005536791,0.000411283,0.0002072585,0.001412697,0.001460882,0.0002019363,0.0001706653,0.0008929459,0.000002028726],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.004106665,"about_ca_system_score_gemma":0.006163489,"about_ca_topic_candidate":true,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00586648,"about_ca_topic_score_gemma":0.0325509,"domain_scores_codex":[0.992521,0.001698247,0.001897902,0.0009714115,0.001960248,0.0009512026],"domain_scores_gemma":[0.9952405,0.002310305,0.0006819927,0.0007908217,0.0005787491,0.000397601],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6742165,0.006190035,0.0147976,0.0002924336,0.0009429751,0.0003124843,0.005838964,0.00006191218,0.0000173041,0.00003968663,0.0000232339,0.2972669],"study_design_scores_gemma":[0.9244431,0.04980676,0.00576666,0.001380152,0.0008349624,0.00001008971,0.01322425,0.0006327107,0.0003965801,0.00006225082,0.00305905,0.0003834152],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9817506,0.006836482,0.000270748,0.0009770663,0.0006683488,0.007989002,0.0009069059,0.00004410062,0.0005567325],"genre_scores_gemma":[0.9936927,0.003721899,0.0002045546,0.0001885561,0.00005750541,0.001646822,0.000139055,0.00006997171,0.0002789695],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2968835,"threshold_uncertainty_score":0.9998339,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4205192276","doi":"10.1177/17588359211072621","title":"Prognostic value of the immune target CEACAM6 in cancer: a meta-analysis","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Radiopharmaceutical Chemistry and Applications","field":"Medicine","cited_by":21,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Instituto de Salud Carlos III; Junta de Comunidades de Castilla-La Mancha","keywords":"Immunoglobulin superfamily; Carcinoembryonic antigen; Medicine; Cell adhesion molecule; Immune system; Antibody; Cancer research; Cell adhesion; Cancer; Immunology; Oncology; Cell; Bioinformatics; Internal medicine; Biology; Genetics","authors":[{"name":"Miguel Burgos","is_ca":false},{"name":"Iván Cavero‐Redondo","is_ca":false},{"name":"Celia Álvarez‐Bueno","is_ca":false},{"name":"Eva María Galán‐Moya","is_ca":false},{"name":"Atanasio Pandiella","is_ca":false},{"name":"Eitan Amir","is_ca":true},{"name":"Alberto Ocaña","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.05935806131821707,"gpt":0.4326514725263498,"spread":0.3732934112081328,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009832904,0.0001320445,0.001010497,0.0001014484,0.00007032765,0.000001219204,0.000432433,0.0001000656,0.005193698],"category_scores_gemma":[0.000175682,0.00008609435,0.0004143541,0.001640789,0.0004358816,0.00002964512,0.0001405325,0.0009286456,0.000001290826],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002551074,"about_ca_system_score_gemma":0.0004628793,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005254653,"about_ca_topic_score_gemma":0.00003583126,"domain_scores_codex":[0.9977821,0.0004234381,0.0006319181,0.0002796729,0.0006024761,0.0002804431],"domain_scores_gemma":[0.9985923,0.0007510713,0.0001839991,0.0003364318,0.00002838735,0.0001078374],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.004167656,0.0221494,0.334122,0.001206059,0.1011359,0.0009346469,0.00474276,0.1079321,0.02463207,0.06273614,0.0001553686,0.336086],"study_design_scores_gemma":[0.01072218,0.001443849,0.06418328,0.00006010466,0.1472749,0.0003545073,0.002536429,0.0548809,0.01757495,0.03025585,0.6699003,0.0008127632],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.5031008,0.3413564,0.002461187,0.1374717,0.0005708613,0.003073138,0.0001094233,0.00008494613,0.01177153],"genre_scores_gemma":[0.9940984,0.001193134,0.0003476553,0.003067767,0.00004105428,0.00104671,0.00001022045,0.00001020423,0.0001848472],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6697449,"threshold_uncertainty_score":0.9957157,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4327652478","doi":"10.1177/17588359231160141","title":"Direct GDP-KRAS <sup>G12C</sup> inhibitors and mechanisms of resistance: the tip of the iceberg","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Protein Kinase Regulation and GTPase Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":20,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research; Regeneron Pharmaceuticals; Sanofi; Daiichi-Sankyo; Amgen; Pfizer; Genentech; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; KRAS; Iceberg; Cancer research; Internal medicine; Pharmacology; Cancer; Physics","authors":[{"name":"Joshua C. Rosen","is_ca":true},{"name":"Adrian G. Sacher","is_ca":true},{"name":"Ming‐Sound Tsao","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.02494405273547091,"gpt":0.3498188310208574,"spread":0.3248747782853865,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001497769,0.0002857802,0.001100108,0.00007522433,0.00007089787,0.000003910901,0.000574412,0.0006401592,0.00004163884],"category_scores_gemma":[0.0004245225,0.0001550649,0.0002719115,0.0003914773,0.0008229697,0.000004329922,0.0002831646,0.0004140637,0.000002183208],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00003644215,"about_ca_system_score_gemma":0.0005888582,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000006906623,"about_ca_topic_score_gemma":0.0001549324,"domain_scores_codex":[0.9971307,0.0009370376,0.0008509226,0.0003872851,0.0004247246,0.0002693149],"domain_scores_gemma":[0.9983025,0.0004980516,0.0005918663,0.0004780687,0.00005633225,0.00007323365],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0000855397,0.00007907064,0.000004676346,0.00357509,0.0001816977,0.000009984095,0.0000922477,0.00002879807,0.000212897,0.005135029,0.00009860859,0.9904963],"study_design_scores_gemma":[0.0003803843,0.0001790423,0.000003160435,0.003271501,0.0001849497,0.00001910356,0.0000935901,0.0000228972,0.001040515,0.003293368,0.9913497,0.000161783],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00007832313,0.9969329,0.0007804271,0.0003181447,0.0002500711,0.0007140775,0.00002602223,0.000009201632,0.0008908691],"genre_scores_gemma":[0.003767502,0.9950446,0.0001381883,0.0002788594,0.0002031105,0.0001322793,0.00002520012,0.00003913125,0.0003710861],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9912511,"threshold_uncertainty_score":0.6323363,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4379383902","doi":"10.1177/17588359231175440","title":"Targeting HER2-low in metastatic breast cancer: an evolving treatment paradigm","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"HER2/EGFR in Cancer Research","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia; BC Cancer Agency; Ottawa Hospital; Sinai Health System; University of Toronto; University of Alberta; University of Calgary","funders":"National Cancer Institute; Mylan; AstraZeneca Canada; Seagen; Gilead Sciences; Amgen; Pfizer; AstraZeneca; Eli Lilly and Company","keywords":"Medicine; Trastuzumab; Oncology; Breast cancer; Metastatic breast cancer; Internal medicine; Clinical trial; Biomarker; Disease; Hormone receptor; Pertuzumab; Cancer; Population; Human Epidermal Growth Factor Receptor 2","authors":[{"name":"Charlie Yang","is_ca":true},{"name":"Christine Brezden‐Masley","is_ca":true},{"name":"Anil A. Joy","is_ca":true},{"name":"Sandeep Sehdev","is_ca":true},{"name":"Shanu Modi","is_ca":false},{"name":"Christine Simmons","is_ca":true},{"name":"Jan‐Willem Henning","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1399657081691481,"gpt":0.5367814479793399,"spread":0.3968157398101919,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002904213,0.0007944117,0.004872832,0.000821982,0.00007898566,0.00002331392,0.0007625967,0.0008093033,0.002724926],"category_scores_gemma":[0.0004856364,0.0005733558,0.0003494075,0.001678409,0.0006535845,0.0002050067,0.0001562882,0.002269163,0.0001810645],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.006529665,"about_ca_system_score_gemma":0.008106926,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009310761,"about_ca_topic_score_gemma":0.003384941,"domain_scores_codex":[0.9917804,0.002156396,0.001973627,0.00120412,0.001370319,0.001515162],"domain_scores_gemma":[0.9952343,0.002778296,0.0004622975,0.0006966321,0.00008077401,0.0007477289],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.000138863,0.0009627937,0.0003088561,0.01113775,0.0002778851,0.003336247,0.0003482132,0.00003074787,3.891265e-7,0.000109322,0.00004326437,0.9833057],"study_design_scores_gemma":[0.002587075,0.001460246,0.00008755859,0.0261721,0.0005596871,0.0006192231,0.0002536599,0.001261076,3.102323e-7,0.0006816033,0.9658419,0.0004755306],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00003983862,0.9937808,0.00008090686,0.001874291,0.0009420016,0.002541334,0.00007117543,0.0001388989,0.0005307395],"genre_scores_gemma":[0.0001460247,0.9943541,0.000456205,0.0006221038,0.0008927659,0.002917819,0.0001564016,0.0002133401,0.0002412226],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9828301,"threshold_uncertainty_score":0.9996718,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3203798531","doi":"10.1177/17588359211039928","title":"ALBI score and outcomes in patients with hepatocellular carcinoma: <i>post hoc</i> analysis of the randomized controlled trial KEYNOTE-240","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Post-hoc analysis; Internal medicine; Placebo; Pembrolizumab; Hazard ratio; Hepatocellular carcinoma; Confidence interval; Hepatology; Gastroenterology; Liver function; Sorafenib; Cancer; Pathology","authors":[{"name":"Arndt Vogel","is_ca":false},{"name":"Philippe Merle","is_ca":false},{"name":"Chris Verslype","is_ca":false},{"name":"Richard S. Finn","is_ca":false},{"name":"Andrew X. Zhu","is_ca":false},{"name":"Ann‐Lii Cheng","is_ca":false},{"name":"Stephen L. Chan","is_ca":false},{"name":"Thomas Yau","is_ca":false},{"name":"Baek‐Yeol Ryoo","is_ca":false},{"name":"Jennifer J. Knox","is_ca":true},{"name":"Bruno Daniele","is_ca":false},{"name":"Shukui Qin","is_ca":false},{"name":"Ziwen Wei","is_ca":false},{"name":"Yanna R. Miteva","is_ca":false},{"name":"Usha Malhotra","is_ca":false},{"name":"Abby B. Siegel","is_ca":false},{"name":"Masatoshi Kudo","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01850701140717144,"gpt":0.2851676526289131,"spread":0.2666606412217417,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001273228,0.000273609,0.003531484,0.0002762017,0.000043321,0.000006111241,0.0001592608,0.0002701604,0.000455199],"category_scores_gemma":[0.0007433671,0.0001396886,0.0005059661,0.0009221406,0.0006993076,0.00006831799,0.00007755653,0.0003995034,0.00000171237],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001285873,"about_ca_system_score_gemma":0.0005917323,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00005512315,"about_ca_topic_score_gemma":0.000416474,"domain_scores_codex":[0.9961596,0.001340637,0.001017825,0.0004014347,0.0007445278,0.0003359478],"domain_scores_gemma":[0.9966027,0.002362366,0.000337316,0.0003698479,0.0001728047,0.000154968],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.412991,0.0009490505,0.5746332,0.00002325977,0.0008855336,0.0001613264,0.0001945212,0.000001704186,0.000004024349,0.00008180254,3.6326e-7,0.01007419],"study_design_scores_gemma":[0.8746054,0.001912853,0.1160181,0.00007376271,0.0040446,0.000006004923,0.00008876459,0.002468779,0.00005774183,0.0001328841,0.0004541795,0.0001368901],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9839346,0.00999792,0.0000697079,0.002015358,0.0001927768,0.003250171,0.000006738707,0.00001100112,0.000521721],"genre_scores_gemma":[0.9970869,0.0009204058,0.0001574974,0.001224983,0.00003288708,0.0003889483,0.0000474991,0.00001810524,0.0001227745],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4616144,"threshold_uncertainty_score":0.5696336,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3129833506","doi":"10.1177/1758835921992987","title":"Elevated risk of colorectal, liver, and pancreatic cancers among HCV, HBV and/or HIV (co)infected individuals in a population based cohort in Canada","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Hepatitis B Virus Studies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"Simon Fraser University; Vancouver General Hospital; University of Waterloo; BC Centre for Disease Control; University of British Columbia","funders":"Canadian Institutes of Health Research; Michael Smith Health Research BC","keywords":"Medicine; Internal medicine; Hepatitis C virus; Pancreatic cancer; Colorectal cancer; Gastroenterology; Population; Cohort; Hazard ratio; Liver cancer; Hepatitis B virus; Hepatitis C; Cancer; Hepatitis B; Confidence interval; Immunology; Virus","authors":[{"name":"Maryam Darvishian","is_ca":true},{"name":"Zahid A Butt","is_ca":true},{"name":"Stanley Wong","is_ca":true},{"name":"Eric M. Yoshida","is_ca":true},{"name":"Jaskaran Khinda","is_ca":true},{"name":"Michael Otterstatter","is_ca":true},{"name":"Amanda Yu","is_ca":true},{"name":"Mawuena Binka","is_ca":true},{"name":"Carmine Rossi","is_ca":true},{"name":"Geoffrey McKee","is_ca":true},{"name":"Margo Pearce","is_ca":true},{"name":"Maria Alvarez","is_ca":true},{"name":"Jason Wong","is_ca":true},{"name":"Darrel Cook","is_ca":true},{"name":"Troy Grennan","is_ca":true},{"name":"Jane A. Buxton","is_ca":true},{"name":"Mark Tyndall","is_ca":true},{"name":"Ryan Woods","is_ca":true},{"name":"Mel Krajden","is_ca":true},{"name":"Parveen Bhatti","is_ca":true},{"name":"Naveed Z. Janjua","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01511866858711174,"gpt":0.319809794254882,"spread":0.3046911256677703,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007019243,0.0001770415,0.0009584893,0.0001852541,0.00003258379,0.000002448486,0.00006541457,0.0001907595,0.0002953525],"category_scores_gemma":[0.001676398,0.0001481215,0.00001968953,0.0005777805,0.000323258,0.0000746261,0.00004529249,0.0004748222,5.050523e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001465047,"about_ca_system_score_gemma":0.003300424,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.6603988,"about_ca_topic_score_gemma":0.9904844,"domain_scores_codex":[0.9975594,0.0006679987,0.0006678156,0.0003355679,0.0004207553,0.0003484208],"domain_scores_gemma":[0.9976253,0.001827978,0.0002087828,0.0001277158,0.00006418069,0.0001460345],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.000379372,0.0001229867,0.9564727,0.0001364178,0.00007543405,0.0005750727,0.0003704301,0.00006551779,0.00004219684,0.00001424032,0.00001095014,0.04173469],"study_design_scores_gemma":[0.004263219,0.000409207,0.9864952,0.0004544675,0.0001076491,0.000023404,0.0002737486,0.006722022,0.0001199839,0.000108197,0.0008897262,0.0001331681],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918237,0.006769692,0.00003499637,0.0004255779,0.00009373158,0.0005763071,0.0000286209,0.0000128704,0.0002345512],"genre_scores_gemma":[0.9747735,0.02380951,0.000418211,0.0007850658,0.00001776116,0.0001189885,0.00005189118,0.00001505099,0.00001003222],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3300856,"threshold_uncertainty_score":0.6040218,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4205632236","doi":"10.1177/17588359211059601","title":"Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline <i>BRCA1</i> / <i>2</i> mutations and hormone receptor status from the phase-3 BROCADE3 trial","year":2021,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"PARP inhibition in cancer therapy","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Aptitude Health; AbbVie","keywords":"Hazard ratio; Veliparib; Breast cancer; Metastatic breast cancer; Clinical endpoint; Placebo; BRCA mutation; Germline mutation","authors":[],"retraction":null,"screen_n_in":null,"score":{"opus":0.026685671906535,"gpt":0.392095379246344,"spread":0.365409707339809,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004757318,0.0003472524,0.001311542,0.0001001485,0.00009366125,0.00001104576,0.0001540424,0.000195196,0.0004268583],"category_scores_gemma":[0.0004842977,0.0002232459,0.00006084446,0.0007928552,0.00135639,0.0002138471,0.00006127159,0.0007249322,9.264098e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004997524,"about_ca_system_score_gemma":0.00155639,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005834138,"about_ca_topic_score_gemma":0.002391572,"domain_scores_codex":[0.996232,0.0007517806,0.001138779,0.0006147613,0.0007730335,0.000489621],"domain_scores_gemma":[0.9941836,0.004485149,0.000487937,0.000306542,0.0002373655,0.0002994015],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.3691385,0.003796994,0.007409877,0.00009544042,0.0008220122,0.0001008754,0.003625826,0.0004179586,0.002174849,0.00009134481,0.0001067156,0.6122196],"study_design_scores_gemma":[0.8750046,0.01341814,0.0690365,0.001497107,0.001068886,0.00007965499,0.004839611,0.001581124,0.001738227,0.0009792494,0.02993872,0.0008181622],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9516782,0.03669081,0.003247328,0.005014655,0.0002580963,0.001757726,0.001219166,0.00003153278,0.0001025134],"genre_scores_gemma":[0.9517725,0.04028705,0.003316437,0.003640151,0.0001438537,0.0002893928,0.0004671649,0.00005030734,0.00003315883],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6114015,"threshold_uncertainty_score":0.9103702,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4295904913","doi":"10.1177/17588359221122714","title":"The role of gut microbiome in immune modulation in metastatic renal cell carcinoma","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":17,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Lawson Health Research Institute; Western University","funders":"","keywords":"Medicine; Microbiome; Immunotherapy; Renal cell carcinoma; Gut microbiome; Immune system; Intensive care medicine; Gut flora; Immunology; Oncology; Bioinformatics; Biology","authors":[{"name":"Jasna Deluce","is_ca":true},{"name":"Saman Maleki Vareki","is_ca":true},{"name":"Ricardo Fernandes","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.0327534350615301,"gpt":0.37980260325678,"spread":0.3470491681952499,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002481102,0.0003305115,0.002116028,0.0005003195,0.00004665391,0.000003886159,0.0005112962,0.0003360216,0.0008169693],"category_scores_gemma":[0.0001028845,0.0002195524,0.0003197781,0.001104801,0.0005283276,0.00005785109,0.0001129435,0.001255582,0.000004235585],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001170439,"about_ca_system_score_gemma":0.001625643,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002071776,"about_ca_topic_score_gemma":0.000530423,"domain_scores_codex":[0.9955994,0.001212133,0.001823914,0.0003982013,0.0004992904,0.0004670073],"domain_scores_gemma":[0.9970455,0.001801571,0.0006451209,0.0004192849,0.0000202574,0.00006823592],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0009337611,0.0004382198,0.00008879154,0.001675705,0.00006731976,0.000141303,0.0002681867,0.000005220268,0.0001592829,0.00007326937,0.000002762255,0.9961462],"study_design_scores_gemma":[0.003295549,0.0007693792,0.0003263335,0.001773464,0.0001669022,0.0001521652,0.000362203,0.0001335894,0.0000185712,0.0006510094,0.9921643,0.0001864959],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0008567108,0.9959833,0.00002002294,0.0002544518,0.0004182879,0.001159053,0.00001043092,0.000008793861,0.001288942],"genre_scores_gemma":[0.01086668,0.9881611,0.0001323092,0.0002096134,0.00005886114,0.0003598528,0.00008081868,0.00003997059,0.00009073697],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9959597,"threshold_uncertainty_score":0.8953086,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4286357580","doi":"10.1177/17588359221111705","title":"Tumor Biomarker Testing for Metastatic Colorectal Cancer: a Canadian Consensus Practice Guideline","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Colorectal Cancer Treatments and Studies","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":true},"ca_institutions":"BC Cancer Agency; Ottawa Hospital; Centre Hospitalier de l’Université de Montréal; Queen Elizabeth II Health Sciences Centre; William Osler Health System; University of Alberta; Surrey Memorial Hospital","funders":"Pfizer Canada; Amgen Canada; Thermo Scientific","keywords":"KRAS; Medicine; Colorectal cancer; Biomarker; Oncology; Guideline; Targeted therapy; Biomarker discovery; Cancer; Internal medicine; Bioinformatics; Pathology; Gene; Biology","authors":[{"name":"Irene Yu","is_ca":true},{"name":"Rachel Goodwin","is_ca":true},{"name":"Jonathan M. Loree","is_ca":true},{"name":"Cheryl Mather","is_ca":true},{"name":"Brandon S. Sheffield","is_ca":true},{"name":"Stephanie Snow","is_ca":true},{"name":"Sharlene Gill","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1339412313251146,"gpt":0.491445212441576,"spread":0.3575039811164614,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001816224,0.0006078238,0.003434149,0.0004392774,0.0002695039,0.00001044702,0.0003209357,0.0002645503,0.00195321],"category_scores_gemma":[0.005769026,0.0004492604,0.0003665109,0.0009478049,0.0004899696,0.00005496008,0.0001251321,0.001017176,0.00000942759],"about_ca_system_candidate":true,"about_ca_system_consensus":true,"about_ca_system_score_codex":0.004500579,"about_ca_system_score_gemma":0.0148778,"about_ca_topic_candidate":true,"about_ca_topic_consensus":true,"about_ca_topic_score_codex":0.01270543,"about_ca_topic_score_gemma":0.09420539,"domain_scores_codex":[0.9953873,0.0006978381,0.001558365,0.0007814777,0.0006438783,0.0009311236],"domain_scores_gemma":[0.9876112,0.0106042,0.0007394188,0.0002583198,0.0002289098,0.0005579159],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0006206538,0.0003655685,0.00002420569,0.00265665,0.001051533,0.002659874,0.0001038142,0.000001878074,1.336059e-7,0.00007840582,0.001142137,0.9912952],"study_design_scores_gemma":[0.002766437,0.002773126,0.000007604435,0.002038351,0.003805181,0.002626952,0.000446763,0.0002501506,1.167882e-7,0.0001723219,0.9847336,0.0003794157],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.000006249975,0.980915,0.00004364743,0.005770536,0.001375872,0.003406817,0.0002755049,0.00005531162,0.008151048],"genre_scores_gemma":[0.00003257518,0.980278,0.006113737,0.007112412,0.0003047403,0.00573717,0.0001877904,0.00009657802,0.0001370067],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9909157,"threshold_uncertainty_score":0.9997959,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3195299022","doi":"10.1177/17588359211039052","title":"Novel and emerging approaches in the management of non-muscle invasive urothelial carcinoma","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"","keywords":"Medicine; Urothelial carcinoma; Carcinoma; Cancer research; Oncology; Bladder cancer; Internal medicine; Cancer","authors":[{"name":"Omid Yassaie","is_ca":true},{"name":"Cyrus Chehroudi","is_ca":true},{"name":"Peter C. Black","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.09591219510996234,"gpt":0.4072967351049521,"spread":0.3113845399949898,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000719494,0.0003417915,0.001966502,0.000175712,0.00003110132,0.00000491693,0.0003303746,0.000369084,0.0001246633],"category_scores_gemma":[0.00003412816,0.000210068,0.0001867597,0.0004723827,0.0003837346,0.00004722445,0.00013486,0.0007147522,0.000002933851],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002234106,"about_ca_system_score_gemma":0.0009180022,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004408852,"about_ca_topic_score_gemma":0.0001204518,"domain_scores_codex":[0.9975502,0.0003162193,0.0007823824,0.0004819025,0.0005141363,0.000355196],"domain_scores_gemma":[0.9986497,0.0006335935,0.0002350705,0.0003600366,0.00002157538,0.0001000914],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004947634,0.000625106,0.0001145383,0.008531822,0.0002370455,0.0006631875,0.0007490425,6.198646e-7,5.632887e-7,0.0005924317,0.000003738572,0.9884324],"study_design_scores_gemma":[0.004404988,0.0007598514,0.0007381135,0.01309168,0.001447821,0.0004806655,0.00202426,0.00002402691,0.000002236999,0.000247267,0.9765386,0.0002405038],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001715689,0.9913728,0.0003571829,0.0004953008,0.0002461095,0.001401993,0.00001120613,0.000006711244,0.005937081],"genre_scores_gemma":[0.003726918,0.9937893,0.000992495,0.0007035467,0.0001674255,0.0005059862,0.00003178305,0.0000351834,0.00004740201],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9881919,"threshold_uncertainty_score":0.8566325,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4323063328","doi":"10.1177/17588359231157651","title":"Circulating tumor DNA: toward evolving the clinical paradigm of pancreatic ductal adenocarcinoma","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":13,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Vancouver General Hospital; University of British Columbia Hospital; University of British Columbia; Pancreas Centre (Canada)","funders":"Terry Fox Research Institute; Genome British Columbia; Pancreatic Cancer Canada Foundation; VGH and UBC Hospital Foundation","keywords":"Liquid biopsy; Medicine; Pancreatic ductal adenocarcinoma; Druggability; Pancreatic cancer; Disease; Clinical trial; Genomics; Bioinformatics; Internal medicine; Oncology; Cancer; Genome; Gene; Biology; Genetics","authors":[{"name":"James T. Topham","is_ca":true},{"name":"Daniel J. Renouf","is_ca":true},{"name":"David F. Schaeffer","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.08646251333694421,"gpt":0.4371774313894952,"spread":0.350714918052551,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001843268,0.0003964113,0.001959233,0.00009108686,0.00006186496,0.0000112632,0.0009327668,0.0007097972,0.0000712512],"category_scores_gemma":[0.00185072,0.0002756154,0.0005240987,0.0003168051,0.0008161755,0.000004997378,0.0004003395,0.0008231902,0.00002109812],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001302656,"about_ca_system_score_gemma":0.002093,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00002358276,"about_ca_topic_score_gemma":0.0001338133,"domain_scores_codex":[0.9959801,0.0007799402,0.001694152,0.0006565268,0.00037585,0.0005133645],"domain_scores_gemma":[0.9959116,0.002453212,0.00079524,0.0006186286,0.0000509532,0.0001703606],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00004514596,0.0001406462,0.0006147249,0.002423421,0.0003387934,0.0002874034,0.00007045063,0.00001078612,0.000004345391,0.0007598905,0.0001133578,0.995191],"study_design_scores_gemma":[0.0006879863,0.0007111605,0.0002601287,0.002283343,0.0005818033,0.0004110167,0.0001170549,0.0001018897,0.000002781578,0.001696241,0.9927979,0.0003487387],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0008860347,0.9959915,0.0004573852,0.0002366739,0.001248256,0.0006763604,0.00002844962,0.00001498631,0.0004603635],"genre_scores_gemma":[0.0072041,0.9903283,0.0001796341,0.0005738584,0.001334657,0.0001856475,0.00008710754,0.00007867091,0.0000280944],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9948423,"threshold_uncertainty_score":0.9999696,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4361988864","doi":"10.1177/17588359231156382","title":"A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":12,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital","funders":"FP7 Health; Pharmacyclics; Sanofi Genzyme; Genentech; Daiichi Sankyo Europe; National Cancer Institute; Servier; AstraZeneca; Institut National Du Cancer; Canadian Cancer Society; Foundation Medicine; Fondation ARC pour la Recherche sur le Cancer; Seagen; Puma Biotechnology; Actuate Therapeutics; Symphogen; Pfizer; Incyte; Grifols; EQRx; BeiGene; European Commission; Sanofi; Halozyme; Chugai Pharmaceutical; Israel Science Foundation; Ipsen; Array BioPharma; Bristol-Myers Squibb; Eli Lilly and Company; American Society of Clinical Oncology; Instituto de Salud Carlos III; Amgen; Novartis Pharmaceuticals Corporation; Les Laboratories Pierre Fabre","keywords":"Medicine; Oncology; Clinical trial; Internal medicine; Immunotherapy; Metastasis; Cancer","authors":[{"name":"Vladimir Lazar","is_ca":false},{"name":"Baolin Zhang","is_ca":false},{"name":"Shai Magidi","is_ca":false},{"name":"Christophe Le Tourneau","is_ca":false},{"name":"Eric Raymond","is_ca":false},{"name":"Michel Ducreux","is_ca":false},{"name":"Catherine Bresson","is_ca":false},{"name":"Jacques Raynaud","is_ca":false},{"name":"Fanny Wunder","is_ca":false},{"name":"Amir Onn","is_ca":false},{"name":"Enriqueta Felip","is_ca":false},{"name":"Josep Tabernero","is_ca":false},{"name":"Gerald Batist","is_ca":true},{"name":"Razelle Kurzrock","is_ca":false},{"name":"Eitan Rubin","is_ca":false},{"name":"Richard L. Schilsky","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1778064220423873,"gpt":0.5108081939300281,"spread":0.3330017718876408,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01600995,0.0002900724,0.002068461,0.0005411098,0.0000627172,0.00001186205,0.0002917112,0.0007814393,0.0002692219],"category_scores_gemma":[0.001152673,0.0002235188,0.0002620879,0.00113585,0.0008023204,0.0001116606,0.00006678901,0.00102895,0.0000261249],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004044546,"about_ca_system_score_gemma":0.0009373907,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003476799,"about_ca_topic_score_gemma":0.0002078101,"domain_scores_codex":[0.9934338,0.002677278,0.002093633,0.0006702619,0.0004491016,0.0006759679],"domain_scores_gemma":[0.9938875,0.005072866,0.0002377393,0.0003326684,0.00004496236,0.0004242814],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0103993,0.001292511,0.002787723,0.00007028287,0.0001783879,0.0001819283,0.001821674,0.00008451656,0.0007656322,0.00116808,0.000190435,0.9810596],"study_design_scores_gemma":[0.03882923,0.006083194,0.03002806,0.0003116846,0.0002599714,0.0005162099,0.004421364,0.008778416,0.00006590941,0.005375455,0.904776,0.0005545192],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.67342,0.1153553,0.05079271,0.1162963,0.006457215,0.009559622,0.0000492289,0.0006750655,0.02739456],"genre_scores_gemma":[0.7610797,0.1881047,0.01034595,0.03788986,0.0007554988,0.001108347,0.00005569245,0.000093842,0.0005663504],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.980505,"threshold_uncertainty_score":0.911483,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4383647203","doi":"10.1177/17588359231183668","title":"Radiation and immune checkpoint inhibitors in the treatment of oligometastatic non-small-cell lung cancer: a practical review of rationale, recent data, and research questions","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Sunnybrook Hospital; London Health Sciences Centre","funders":"","keywords":"SABR volatility model; Medicine; Lung cancer; Oncology; Clinical trial; Radiation therapy; Narrative review; Internal medicine; Medical physics; Intensive care medicine","authors":[{"name":"Sondos Zayed","is_ca":true},{"name":"Alexander V. Louie","is_ca":true},{"name":"Daniel Breadner","is_ca":true},{"name":"David A. Palma","is_ca":true},{"name":"Rohann Correa","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1472021680698072,"gpt":0.5244359166054591,"spread":0.3772337485356519,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.005669975,0.0002363021,0.001828572,0.0003568941,0.00004095773,0.000004642819,0.0002354729,0.000267144,0.00009222154],"category_scores_gemma":[0.0007591381,0.0001413096,0.00009970129,0.001241649,0.0006987919,0.00007411485,0.00007607191,0.0006243894,0.000001101352],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005560272,"about_ca_system_score_gemma":0.003138037,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002627259,"about_ca_topic_score_gemma":0.0003881828,"domain_scores_codex":[0.9954771,0.001592452,0.001598247,0.0004128009,0.0006419831,0.0002774479],"domain_scores_gemma":[0.9942387,0.004490885,0.0005841056,0.0004799468,0.0001216142,0.000084771],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002292346,0.0007326544,0.0000456148,0.04587509,0.0001974469,0.00004838842,0.0005462608,1.508575e-7,0.000003605954,0.00005616391,0.00006512815,0.9522003],"study_design_scores_gemma":[0.002325491,0.001381463,0.0001380479,0.05861427,0.0008508029,0.0001320382,0.000284135,0.0001191704,0.00000605728,0.00009943357,0.9359373,0.0001117918],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001059715,0.9902874,0.00004021972,0.005888887,0.000190765,0.003282996,0.00004769682,0.00000559609,0.000150519],"genre_scores_gemma":[0.00003075559,0.9980627,0.0003408341,0.0002887726,0.0001159402,0.0009161289,0.0001923963,0.00002359627,0.00002885018],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9520885,"threshold_uncertainty_score":0.5762436,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4321795635","doi":"10.1177/17588359231152843","title":"Quality of life with ribociclib <i>versus</i> abemaciclib as first-line treatment of HR+/HER2− advanced breast cancer: a matching-adjusted indirect comparison","year":2023,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Novartis (Canada)","funders":"National Cancer Institute; Eli Lilly and Company; Novartis Institutes for BioMedical Research; Astex Pharmaceuticals; Novartis Pharmaceuticals Corporation; Pfizer","keywords":"Medicine; Breast cancer; Internal medicine; Quality of life (healthcare); Oncology; Placebo; Cancer; Hazard ratio; Clinical trial; Confidence interval; Alternative medicine; Pathology","authors":[{"name":"Hope S. Rugo","is_ca":false},{"name":"Victoria Harmer","is_ca":false},{"name":"Joyce O’Shaughnessy","is_ca":false},{"name":"Komal Jhaveri","is_ca":false},{"name":"Sara M. Tolaney","is_ca":false},{"name":"Fátima Cardoso","is_ca":false},{"name":"Aditya Bardia","is_ca":false},{"name":"Vikalp Kumar Maheshwari","is_ca":false},{"name":"Sandeep Tripathi","is_ca":false},{"name":"Sina Haftchenary","is_ca":true},{"name":"Purnima Pathak","is_ca":false},{"name":"Peter A. Fasching","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06506842105089145,"gpt":0.4343277424711693,"spread":0.3692593214202778,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0007325589,0.0005267573,0.00273952,0.0003401358,0.0000839114,0.000003812692,0.0003823182,0.0003884418,0.0007616286],"category_scores_gemma":[0.0001814492,0.0003895655,0.0002148258,0.001519997,0.001226074,0.0002269644,0.00008118843,0.0005087343,0.00002080816],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008122512,"about_ca_system_score_gemma":0.001403577,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0006269435,"about_ca_topic_score_gemma":0.004144311,"domain_scores_codex":[0.9952247,0.0004209315,0.001619727,0.0007013065,0.00123338,0.000800001],"domain_scores_gemma":[0.995541,0.002092537,0.001024322,0.0006239654,0.0002484908,0.0004696841],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.04871656,0.002594387,0.06100689,0.0006153692,0.0007843386,0.0001267534,0.003169883,0.003591788,0.001038259,0.0005346287,0.00000866717,0.8778125],"study_design_scores_gemma":[0.2597911,0.0602462,0.3574496,0.00494958,0.001709096,0.0006932796,0.01994865,0.004180342,0.01328768,0.01110481,0.2636362,0.003003481],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9652327,0.02057975,0.001591985,0.008743074,0.0007790687,0.001407825,0.000143514,0.0003023813,0.001219755],"genre_scores_gemma":[0.9763013,0.02039774,0.001449475,0.0009178669,0.0002349131,0.0004071979,0.00007014559,0.00008733965,0.0001340094],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.874809,"threshold_uncertainty_score":0.9998556,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4383647369","doi":"10.1177/17588359231183676","title":"Clinical trial reform in the post-COVID era","year":2023,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Telemedicine and Telehealth Implementation","field":"Medicine","cited_by":11,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"Clinical trial; Medicine; Telehealth; Pandemic; Health care; Telemedicine; Coronavirus disease 2019 (COVID-19); Pathology; Political science; Disease","authors":[{"name":"Meghan E. Mahoney","is_ca":true},{"name":"Srikala S. Sridhar","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.2428398450424699,"gpt":0.5987535896468035,"spread":0.3559137446043336,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["research_integrity"],"consensus_categories":[],"category_scores_codex":[0.009996858,0.0004232893,0.003440964,0.0005018163,0.00006276141,0.00000660023,0.0007000116,0.001116425,0.0006596149],"category_scores_gemma":[0.002244755,0.0002293142,0.0004132462,0.001148612,0.0005128819,0.00008510811,0.0001031909,0.003602791,0.0001844654],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001140854,"about_ca_system_score_gemma":0.005033107,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001468351,"about_ca_topic_score_gemma":0.001769922,"domain_scores_codex":[0.9916505,0.002300562,0.003495246,0.0006479871,0.001121751,0.0007839751],"domain_scores_gemma":[0.991742,0.006467825,0.0007708381,0.0006036184,0.00005751834,0.000358176],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003210626,0.0005555897,0.00007079719,0.004359937,0.00007390296,0.001033422,0.0002566101,2.72635e-8,3.22253e-9,0.0007896066,0.000177792,0.9894717],"study_design_scores_gemma":[0.03272814,0.006116902,0.0001753687,0.003597511,0.0004558051,0.0003706347,0.0007119826,0.00000590902,5.132627e-9,0.0008622491,0.9547914,0.0001841581],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00009443825,0.9775955,0.00005259582,0.01233618,0.002410599,0.004232876,0.00001013843,0.000079367,0.003188296],"genre_scores_gemma":[0.00005366006,0.9700379,0.0001774692,0.0255877,0.002654745,0.001020892,0.0003107233,0.00006061563,0.00009624084],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9892876,"threshold_uncertainty_score":0.9986959,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4408459343","doi":"10.1177/17588359251323985","title":"Immunotherapy in advanced, <i>KRAS</i> G12C-mutant non-small-cell lung cancer: current strategies and future directions","year":2025,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"","keywords":"KRAS; Medicine; Cancer research; Blockade; Lung cancer; Cancer; Mutation; Immunotherapy; Mutant; Selumetinib; Oncology; Internal medicine; Biology; Colorectal cancer; Receptor","authors":[{"name":"Nadia Ghazali","is_ca":true},{"name":"Marina Chiara Garassino","is_ca":false},{"name":"Natasha B. Leighl","is_ca":true},{"name":"Christine M. Bestvina","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01673988495437135,"gpt":0.4375702361328022,"spread":0.4208303511784309,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0003363886,0.0006399882,0.002684184,0.0004814749,0.0001075829,0.00002449685,0.0002876971,0.0006567,0.000251445],"category_scores_gemma":[0.00002274081,0.0004589601,0.0002562008,0.0009276437,0.0002957831,0.0002017563,0.00007595059,0.001537359,0.000003777676],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001398004,"about_ca_system_score_gemma":0.006854212,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008708786,"about_ca_topic_score_gemma":0.0009060685,"domain_scores_codex":[0.9968831,0.0003047944,0.001077402,0.0007657463,0.0003666282,0.0006023603],"domain_scores_gemma":[0.9982765,0.000687314,0.0003636963,0.0003870156,0.00006951808,0.0002160088],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00009261035,0.0006922992,0.0001767257,0.01189699,0.0002378825,0.0001470929,0.000547697,0.000004985942,9.036324e-7,0.000424773,0.00001894424,0.9857591],"study_design_scores_gemma":[0.00398223,0.0003202034,0.00007707172,0.0167865,0.001181004,0.00008052182,0.0006537507,0.00003237656,7.841655e-7,0.0003095963,0.9762309,0.0003450794],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00005913904,0.988282,0.0002842473,0.001053745,0.002624096,0.002461515,0.0000469557,0.00005879453,0.005129477],"genre_scores_gemma":[0.00005929449,0.99555,0.0003708705,0.0006590605,0.0005822223,0.002417061,0.00009667712,0.00005716448,0.0002076208],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.985414,"threshold_uncertainty_score":0.9997862,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4285270205","doi":"10.1177/17588359221094879","title":"The prognostic impact of bone metastasis in patients with metastatic urothelial carcinoma treated with first-line platinum-based chemotherapy","year":2022,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"St. Michael's Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Metastatic Urothelial Carcinoma; Medicine; Chemotherapy; Urothelial carcinoma; Oncology; Metastasis; Bone metastasis; Internal medicine; First line; Carcinoma; Cancer research; Cancer; Bladder cancer","authors":[{"name":"Husam Alqaisi","is_ca":true},{"name":"Carlos Stecca","is_ca":true},{"name":"Zachary Veitch","is_ca":true},{"name":"Jamila Riromar","is_ca":false},{"name":"Jeenan Kaiser","is_ca":false},{"name":"Nazanin Fallah‐Rad","is_ca":true},{"name":"Di Jiang","is_ca":true},{"name":"Scott North","is_ca":false},{"name":"Sunil Samnani","is_ca":false},{"name":"Nimira Alimohamed","is_ca":false},{"name":"Srikala S. Sridhar","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01586903876166198,"gpt":0.3268424962039521,"spread":0.3109734574422901,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005455213,0.0003121303,0.000913205,0.0002040641,0.0001324114,0.000004911982,0.0002149352,0.00006835027,0.0007824505],"category_scores_gemma":[0.00009494144,0.0001628695,0.000112139,0.0007789157,0.0005111903,0.00006722774,0.00003497889,0.0005136602,0.000001583841],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007013738,"about_ca_system_score_gemma":0.001582364,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003229951,"about_ca_topic_score_gemma":0.0009605931,"domain_scores_codex":[0.9971331,0.0004245556,0.0006154479,0.0003717761,0.0009518234,0.0005033133],"domain_scores_gemma":[0.9979901,0.001132148,0.0002875148,0.0003354127,0.00008979612,0.0001649765],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.02798878,0.003306807,0.8084892,0.00006601062,0.0003850538,0.0002932475,0.0003623108,0.001392904,0.000008929956,0.00002724887,0.000007601328,0.1576719],"study_design_scores_gemma":[0.08473451,0.05805694,0.8479818,0.0002091243,0.0006207875,0.0001110627,0.0003184608,0.001856531,0.00019473,0.0003587458,0.005187856,0.0003694641],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928012,0.003123735,0.0003963159,0.001405277,0.00006374551,0.00184339,0.00006597486,0.0000268395,0.0002734982],"genre_scores_gemma":[0.9975829,0.0002902582,0.0005183535,0.0008121274,0.00002880856,0.0006288258,0.00005992549,0.000051148,0.00002763763],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1573025,"threshold_uncertainty_score":0.8567284,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2118364274","doi":"10.1177/1758834012438214","title":"Exemestane in the prevention setting","year":2012,"lang":"en","type":"article","venue":"Therapeutic Advances in Medical Oncology","topic":"Estrogen and related hormone effects","field":"Biochemistry, Genetics and Molecular Biology","cited_by":10,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true},"ca_institutions":"","funders":"","keywords":"Exemestane; Medicine; Breast cancer; Aromatase; Oncology; Adjuvant; Internal medicine; Clinical trial; Cancer; Gynecology","authors":[{"name":"Jennifer K. Litton","is_ca":false},{"name":"Therese B. Bevers","is_ca":false},{"name":"Banu Arun","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.01053476753346444,"gpt":0.3565464966087671,"spread":0.3460117290753027,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001422232,0.00009251511,0.0001323571,0.00002591463,0.00003025005,0.00000255777,0.0002146004,0.0002776441,0.00004239166],"category_scores_gemma":[0.0001178392,0.00006013752,0.00003903574,0.000122703,0.0001362231,0.000008660264,0.00004213327,0.0003285195,0.0000109981],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002942205,"about_ca_system_score_gemma":0.00008401355,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000002238399,"about_ca_topic_score_gemma":0.00002600457,"domain_scores_codex":[0.9986392,0.0004953881,0.0002138396,0.0001403916,0.00017763,0.0003336122],"domain_scores_gemma":[0.9996002,0.0001270745,0.00005796807,0.0001441153,0.000008581264,0.00006205932],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002121997,0.0006025511,0.0137776,0.00001943978,0.00002310876,0.00004312544,0.0006205588,0.00002507019,0.01072579,0.00187435,0.00009692174,0.9719793],"study_design_scores_gemma":[0.003484722,0.001924373,0.01073453,0.00009860967,0.00003926244,0.0004905203,0.001463985,0.000300108,0.006676084,0.003885347,0.9705418,0.0003606066],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9028655,0.08225638,0.001661276,0.001841128,0.0005284993,0.0003720186,4.4948e-7,0.00001125415,0.01046347],"genre_scores_gemma":[0.9910029,0.00644455,0.0003889883,0.001745068,0.0002787028,0.00005183733,0.00001576239,0.000009000251,0.00006318306],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9716187,"threshold_uncertainty_score":0.2452337,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3211652415","doi":"10.1177/17588359211056306","title":"The dawn of a new era, adjuvant EGFR inhibition in resected non-small cell lung cancer","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta; University of Ottawa; Juravinski Cancer Centre; Queen Elizabeth II Health Sciences Centre; William Osler Health System; McMaster University; Ottawa Hospital; University Health Network; Dalhousie University; University of Toronto; Princess Margaret Cancer Centre; BC Cancer Agency","funders":"AstraZeneca Canada; Pfizer","keywords":"Medicine; Lung cancer; Adjuvant; Oncology; Internal medicine; Cancer research; Pathology","authors":[{"name":"Barbara Melosky","is_ca":true},{"name":"Parneet Cheema","is_ca":true},{"name":"Rosalyn A. Juergens","is_ca":true},{"name":"Natasha B. Leighl","is_ca":true},{"name":"Geoffrey Liu","is_ca":true},{"name":"Paul Wheatley‐Price","is_ca":true},{"name":"Adrian G. Sacher","is_ca":true},{"name":"Stephanie Snow","is_ca":true},{"name":"Ming‐Sound Tsao","is_ca":true},{"name":"Deanna McLeod","is_ca":false},{"name":"Quincy S. Chu","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.03545036681411599,"gpt":0.4610218157840545,"spread":0.4255714489699385,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005512788,0.0003519396,0.002198658,0.0002171798,0.00005903522,0.00000725439,0.0002061877,0.0005915093,0.0004719888],"category_scores_gemma":[0.0001641624,0.0002133623,0.0002515706,0.0008261842,0.0002906442,0.00005683107,0.00008831373,0.001207289,0.000005582254],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001421844,"about_ca_system_score_gemma":0.009664581,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004125367,"about_ca_topic_score_gemma":0.003746529,"domain_scores_codex":[0.9969339,0.0004501578,0.001184138,0.0004743543,0.0004826314,0.0004748617],"domain_scores_gemma":[0.9975887,0.001209016,0.0004863869,0.0003954066,0.0001014182,0.0002190923],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00008475129,0.0004017312,0.0001074335,0.003666518,0.0002028,0.0004961147,0.0005785919,0.000007144216,0.00000204028,0.000161314,0.0002319027,0.9940597],"study_design_scores_gemma":[0.003562291,0.0004296944,0.00007915027,0.01995692,0.001280261,0.00008885591,0.0002235325,0.00006966002,0.000009148806,0.0002090135,0.9739121,0.0001793275],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0001659389,0.9922226,0.0002821173,0.001407496,0.000760255,0.00157845,0.00001692382,0.00001602667,0.003550174],"genre_scores_gemma":[0.000282933,0.9965313,0.0003566972,0.0006348309,0.0003408997,0.0006863312,0.0001360165,0.00004723807,0.0009837414],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9938803,"threshold_uncertainty_score":0.9959497,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3208960913","doi":"10.1177/17588359211051870","title":"Should androgen deprivation therapy and other systemic treatments be used in men with prostate cancer and a rising PSA post-local treatments?","year":2021,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Prostate Cancer Treatment and Research","field":"Medicine","cited_by":8,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"","keywords":"Medicine; Prostate cancer; Androgen deprivation therapy; Oncology; Systemic therapy; Hormone therapy; Internal medicine; Clinical trial; Radiation therapy; Prostate-specific antigen; Disease; Cancer; Breast cancer","authors":[{"name":"Anna Patrikidou","is_ca":false},{"name":"Thomas Zilli","is_ca":false},{"name":"Giulia Baciarello","is_ca":false},{"name":"Safae Terisse","is_ca":false},{"name":"Zineb Hamilou","is_ca":true},{"name":"Karim Fizazi","is_ca":false}],"retraction":null,"screen_n_in":null,"score":{"opus":0.1020539174751776,"gpt":0.459568545127229,"spread":0.3575146276520514,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0005357013,0.0005947893,0.002576159,0.000356316,0.00007498996,0.00002258091,0.0001365728,0.000629831,0.0001263344],"category_scores_gemma":[0.00003077335,0.0003447213,0.0001052674,0.0005284166,0.0006349725,0.0001368534,0.00007207219,0.0007185525,0.000001775862],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001494566,"about_ca_system_score_gemma":0.001893429,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003114477,"about_ca_topic_score_gemma":0.0005409923,"domain_scores_codex":[0.9965146,0.0006155499,0.0007460777,0.000845045,0.0006551335,0.0006236564],"domain_scores_gemma":[0.9984609,0.0005932983,0.0002813324,0.0002960153,0.00007058071,0.0002978971],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001322942,0.0005642129,0.01229371,0.002059635,0.001012288,0.001157643,0.001090362,0.000001161953,0.000004260625,0.00003419768,0.000003207165,0.9804564],"study_design_scores_gemma":[0.03469735,0.005411067,0.0009282951,0.03447172,0.002086271,0.002248523,0.001747422,0.0001678656,0.00003301674,0.0001535032,0.9172835,0.000771515],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01804974,0.9772992,0.00003042286,0.0009942105,0.00007106841,0.003204205,0.00004860086,0.00003115359,0.0002714192],"genre_scores_gemma":[0.002695214,0.994127,0.000141024,0.0007193576,0.00008238311,0.001676139,0.0001505146,0.00009003445,0.0003183188],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9796849,"threshold_uncertainty_score":0.9999005,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4312211783","doi":"10.1177/17588359221143975","title":"Circulating tumor DNA in early-stage colon cancer: ready for prime time or needing refinement?","year":2022,"lang":"en","type":"review","venue":"Therapeutic Advances in Medical Oncology","topic":"Cancer Genomics and Diagnostics","field":"Biochemistry, Genetics and Molecular Biology","cited_by":8,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of British Columbia","funders":"BC Cancer Foundation; Michael Smith Health Research BC","keywords":"Medicine; Liquid biopsy; Colorectal cancer; Stage (stratigraphy); Oncology; Minimal residual disease; Circulating tumor DNA; Internal medicine; Cancer; Clinical trial; Disease; Adjuvant; Leukemia","authors":[{"name":"João Paulo Solar Vasconcelos","is_ca":true},{"name":"Mélina Boutin","is_ca":true},{"name":"Jonathan M. Loree","is_ca":true}],"retraction":null,"screen_n_in":null,"score":{"opus":0.06832000875268691,"gpt":0.4248725844434207,"spread":0.3565525756907338,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001110974,0.0004203653,0.001534707,0.0001755456,0.00008970885,0.00001406874,0.0006373194,0.0005267427,0.0007967008],"category_scores_gemma":[0.0006754167,0.0003664268,0.0002024946,0.0003170343,0.0001826895,0.000006981978,0.0003304794,0.0006374899,0.000006013945],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000759058,"about_ca_system_score_gemma":0.002503449,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000104641,"about_ca_topic_score_gemma":0.0009028848,"domain_scores_codex":[0.9969423,0.0002928978,0.001049899,0.0007546744,0.0003076685,0.0006526039],"domain_scores_gemma":[0.9978536,0.001023636,0.0005739742,0.0003629455,0.00003372608,0.0001521258],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0002700476,0.0001677278,0.00003094666,0.001325633,0.00008390372,0.0001605213,0.00006464015,0.00004123336,0.00007422281,0.0001553949,0.00009775169,0.997528],"study_design_scores_gemma":[0.001419169,0.001237071,0.000003141909,0.0009480476,0.0001409238,0.00005569835,0.00005504446,0.000154038,0.00001844234,0.00009066029,0.9954671,0.0004106507],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0007788051,0.9953741,0.0001764292,0.0001381445,0.0008667315,0.001436418,0.0001822442,0.00001494278,0.001032174],"genre_scores_gemma":[0.0001674099,0.9947389,0.0004132824,0.001064757,0.0006796758,0.001946664,0.0004486596,0.00009086957,0.0004497454],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9971173,"threshold_uncertainty_score":0.9998788,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}